Categories
Report

(Nasdaq: OKYO) Profile

OUR NEW PROFILE IS:   (NASDAQ: OKYO)

OKYO REVERSED OFF OF THE 52 WEEK LOWS AND HAS CLOSED GREEN 8 OF THE LAST 9 ON LIGHT INTEREST

OKYO HAS JUST 8.55 MILLION SHARES IN THE ENTIRE FLOAT

_______________________________

Hello Everyone,

We have one last profile for you to watch as we head into the weekend.  It certainly has been a busy week for us here but we were able to watch some significant movers in the market.

We have another profile that we have never before profiled on this newsletter before.

Pull up OKYO Immediately. 

Take a look at the chart below.  This one bounced off of the 52 week lows and has been moving up on light interest which is a very bullish sign for this one.

OKYO Pharma Limited is a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain. The Company’s lead candidate to treat dry eye disease, OK-101, is currently in Phase II clinical trials in the US.

A range of ocular diseases, like glaucoma, uveitis and retinal diseases are most prevalent in the geriatric population, and rates of disease are increasing as the population ages. One of the most common ocular diseases is dry eye disease (DED). It affects almost 50 million people in the US, and the global market for DED was worth $4.5 billion in 2022. It is predicted to reach $6.3 billion by 2028, at a compound annual growth rate (CAGR) of 5.67% during the forecast period.

OKYO Pharma Ltd. (NASDAQ: OKYO) is a biopharma leading the way when it comes to developing novel treatments for DED and ocular pain. Founded in 2018, the company was able to bypass phase 1 safety trials and has begun screening patients for its phase 2 efficacy trials.

The trial includes 240 patients, and OKYO anticipates having topline data on its drug, OK-101, in Quarter 4 of 2023. OK-101 uses a novel chemerin receptor that both acts as an anti-inflammatory agent and reduces corneal neuropathic pain in the patient. As the treatment is administered topically as eye drops, there is almost no risk of systemic exposure or risk of the treatment getting into the bloodstream.

If the trial meets its pre-specified endpoints, this could contribute data toward registration trials, and speed up OK-101’s timeline for approval from the Food and Drug Administration (FDA).

The company is laser-focused on bringing its treatment to market, as it believes the treatment has significant potential in the sector. With recent acquisitions indicating a commitment from big biopharmaceuticals to the ophthalmology market, there may be many eyes watching the progress of OKYO’s phase 2 trials.

In 2018, OKYO successfully obtained (via assignment from Panetta Partners Limited, a related party) an exclusive license from On Target Therapeutics (OTTx) to patents owned or controlled by OTTx and a sub-license from OTTx to certain patents licensed by OTTx from Tufts Medical Center (TMC) to support its ophthalmic disease drug programs. These licenses gave OKYO the right to exploit the IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation such as DED with lipid-linked chemerin analogues. OKYO also has a license from TMC to a separate IP estate for treating symptoms of ocular neuropathic pain, uveitis and associated pain. The scope of the TMC IP granted use through the sublicense with OTT is commensurate with the scope of use of the IP granted to OTT from TMC. This intellectual property, which includes 3 patents related to OK-101 including technology, dry eye, and neuropathic pain, forms the basis of OKYO’s OK-101 program.

CHEMERIN RECEPTOR

  • Chemerin, the endogenous agonist of chemerin receptor ChemR23, a specific member of the G protein coupled receptor (GPCR) class, activates immune cells at the inflammation site.
  • Chemerin activates ChemR23 on circulating monocytes and macrophages, recruiting these cells to the inflammation site.
  • Chemerin is also physiologically cleaved into smaller potent anti-inflammatory peptides that reprogram macrophages to repress inflammation inducing anti-inflammatory cytokines at the inflammatory site, thus restoring normal tissue structure and function.
  • OK-101, OKYO’s lead drug candidate contains a stable chemerin-derived 10-mer peptide as the active anti-inflammatory component of the drug, along with a conjugated lipid component, producing both enhanced agonist potency along with wash resistance.

OK-101 DRUG CANDIDATE

  • One of the major challenges with topical administration of any drug designed for treating OED is drug wash-out through natural processes of tearing and blinking, minimizing drug ‘residence’ time at the ocular site needed to provide a pharmacologic benefit.
  • Membrane Anchored Peptide (MAP) technology enabled the development of a long acting and stable OK-101 drug candidate.
  • OKYO’s lead drug candidate OK-101 consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain.
  • Unique MAP technology enabled the development of a drug with enhanced potency and the expectation of increased drug residence time on the ocular surface.

DRY EYE DISEASE

  • Approximately 5 million people suffer from ocular pain every year.
  • Neuropathic corneal pain, a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available.
  • Current treatments are limited to short term NSAIDs, steroids, and opioids in severe cases. Side effects and the risk of addiction to opioids is a serious concern.
  • The Global ocular pain market is expected to reach $0.5 Billion by 2030.
  • Topical administration of OKYO’s lead drug candidate OK-101 was effective in suppressing corneal pain in a ciliary nerve ligation mouse model of neuropathic corneal pain; exhibiting a potency similar to that of gabapentin, a commonly used oral drug for neuropathic pain that was conversely given by intraperitoneal injection.
  • The pain-relieving potential of a dry eye drug would provide an important benefit to the considerable number of dry eye patients suffering from ocular pain in addition to the existing inflammatory effects of the condition.

ALLERGIC CONJUNCTIVITIS

  • Allergic conjunctivitis, often called ‘pink eye’ is an inflammation of conjunctiva, caused by an allergic reaction to pollen, mold, smoke, dust etc.
  • Up to 40% of the global population suffers from allergic conjunctivitis, which is mostly treated with antihistamines and corticosteroids (2018 annual revenue in US was > $1 Billion). Notably, a significant number of patients do not respond to antihistamines which typically leads to overuse of corticosteroids in these patients.
  • In an animal model, OKYO’s lead drug candidate OK-101 was effective in suppressing ocular inflammation by downregulating key inflammatory CD4+ T cells.
  • Uveitis is the third leading cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can damage vital eye tissue, leading to permanent vision loss.
  • Uveitis is currently treated with corticosteroid eyedrops and injections that reduce inflammation, (2018 annual revenue in US was > $500M). However, the long-term use of corticosteroids causes risk of cataract and glaucoma, requiring close monitoring for their potential side effects.
  • In an animal model, our lead drug candidate OK-101 was effective in suppressing ocular inflammation by downregulating key inflammatory biomarkers CD4+ T cells.
  • Our focus is to suppress the inflammation and pain associated with the uveitis using our lead drug candidate OK-101.

OCULAR PAIN

  • Worldwide, ~700 million patients suffer from dry eye disease. In US, ~30 million patients suffer from dry eye disease.
  • Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected.
  • Prevalence of dry eye is expected to increase substantially due to an aging population and increased use of contact lenses and digital screen time.
  • Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease.

https://platform.twitter.com/embed/Tweet.html?dnt=false&embedId=twitter-widget-1&features=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%3D%3D&frame=false&hideCard=false&hideThread=false&id=1653278148207734784&lang=en&origin=https%3A%2F%2Finsiderfinancial.com%2Fokyo%2F&sessionId=90957c93f1503a1a75e4f2cbfb0b43dec524843f&theme=light&widgetsVersion=aaf4084522e3a%3A1674595607486&width=550px

NEWS

PUBLISHED

JUN 6, 2023

OKYO PHARMA ANNOUNCES RANDOMIZED SEGMENT NOW UNDERWAY IN PHASE 2 CLINICAL TRIAL OF TOPICAL OCULAR OK-101 FOR DRY EYE DISEASE

PUBLISHED

JUN 6, 2023

OKYO PHARMA ANNOUNCES RANDOMIZED SEGMENT NOW UNDERWAY IN PHASE 2 CLINICAL TRIAL OF TOPICAL OCULAR OK-101 FOR DRY EYE DISEASE

PUBLISHED

JUN 1, 2023

EYE CARE SECTOR SEES SEVERAL LARGE ACQUISITIONS – COULD THIS TICKER BE ON ROUTE FOR THE NEXT BIG ACQUISITION?

PUBLISHED

MAY 11, 2023

OKYO PHARMA NOW PARTICIPATING ON THE WEBULL CORPORATE COMMUNICATIONS SERVICE PLATFORM

PUBLISHED

MAY 11, 2023

OKYO PHARMA NOW PARTICIPATING ON THE WEBULL CORPORATE COMMUNICATIONS SERVICE PLATFORM

PUBLISHED

MAY 9, 2023

GOLDMAN SMALL CAP RESEARCH PUBLISHES NEW RESEARCH REPORT ON OKYO PHARMA LIMITED

PUBLISHED

MAY 4, 2023

OKYO PHARMA REACHES MILESTONE WITH FIRST PATIENT SCREENING FOR DRY EYE DISEASE TRIAL

PUBLISHED

MAY 3, 2023

OKYO PHARMA ANNOUNCES PRESENTATIONS AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS 2023) IN SAN DIEGO, CA, MAY 5-8, 2023

PUBLISHED

MAY 3, 2023

OKYO PHARMA ANNOUNCES PRESENTATIONS AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS 2023) IN SAN DIEGO, CA, MAY 5-8, 2023

PUBLISHED

MAY 2, 2023

OKYO PHARMA ANNOUNCES FIRST-PATIENT FIRST-VISIT FOR PHASE 2 TRIAL EVALUATING EFFICACY AND SAFETY OF OK-101 IN PATIENTS WITH DRY EYE DISEASE

PUBLISHED

MAY 2, 2023

OKYO PHARMA ANNOUNCES FIRST-PATIENT FIRST-VISIT FOR PHASE 2 TRIAL EVALUATING EFFICACY AND SAFETY OF OK-101 IN PATIENTS WITH DRY EYE DISEASE

PUBLISHED

APR 25, 2023

OKYO PHARMA ANNOUNCES ACTIVATION OF FIRST CLINICAL TRIAL SITE IN THE U.S. FOR THE PHASE 2 TRIAL EVALUATING OK-101 FOR THE TREATMENT OF DRY EYE DISEASE

PUBLISHED

APR 18, 2023

OKYO PHARMA MANAGEMENT TAKES COMPANY STOCK IN PRIVATE PLACEMENT INSTEAD OF DEFERRED PAY

PUBLISHED

APR 5, 2023

NOTICE OF GENERAL MEETING AND PUBLICATION OF CIRCULAR

MANAGEMENT TEAM

gary-jacob-bwedited-2

GARY JACOB, PHD

CHIEF EXECUTIVE OFFICER/DIRECTOR

Dr. Jacob has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. Dr. Jacob is the Co-Founder and former CEO and Chairman of Synergy Pharmaceuticals. During his time at Synergy, he served as Chairman, Chief Executive Officer and Executive Chairman, and is the co-inventor of Synergy’s FDA-approved drug Trulance® which is currently marketed in the U.S. by Bausch Health, Inc. to treat functional GI disorders. Dr. Jacob is also the former CEO and Managing Director of Immuron Inc., an Australian biotechnology company dual-listed on the Australian ASX exchange and on NASDAQ. Dr. Jacob currently is Chairman of the Board of Hepion Pharmaceuticals, Inc., a public NASDAQ listed company with a drug in clinical development to treat nonalcoholic steatohepatitis (NASH), and is also on the Board of Directors of Cardiff Oncology, Inc., a NASDAQ listed public oncology company. He served as Chief Executive Officer and Director of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013.

Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he was Director of Glycobiology and a Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. Dr. Jacob holds over 30 patents and is the co-inventor of two pharmaceutical drugs which are FDA approved. Dr. Jacob earned a B.S. cum laude in Chemistry from the University of Missouri, St. Louis and holds a Ph.D. in Biochemistry from the University of Wisconsin, Madison.

raj-patil

RAJ PATIL, PHD

CHIEF SCIENTIFIC OFFICER

Dr. Patil brings 30 years of ophthalmic experience and a powerful combination of academic scholarship and pharmaceutical R&D excellence.

Raj previously worked with Ora Inc, as Vice President of Research & Development, where he was responsible for driving all anterior and posterior segment research of Ora’s R&D Institute. Earlier in his career, he worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. His tenure at iVeena included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School and Principal Investigator at Singapore Eye Research Institute.

Raj also held a number of leadership roles at Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology glaucoma and retina research. Prior to joining the business world, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology & Genetics at University of Nebraska Medical Centre in Omaha and as an Assistant Professor of Ophthalmology, Molecular Biology & Pharmacology at Washington University in St. Louis.

Raj received his PhD in Biochemistry from National Chemical Laboratory/University of Pune, India and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor, MI. He is the recipient of Olga Keith Wiess Special Scholar Award from Research to Prevent Blindness Foundation and NIH Director’s New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles and serves as reviewer and editorial board member for numerous journals and is frequently invited to lecture at academic and industry events.

kereen

KEEREN SHAH

CHIEF FINANCIAL OFFICER

Keeren Shah serves as our Chief Financial Officer. Ms. Shah currently also serves as the Finance Director of Tiziana Life Sciences LTD, Accustem Sciences Limited and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining the Company, Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as well as leading and participating in key transformation programmes and Visa Inc.’s initial public offering. Before joining Visa, Ms. Shah also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of Arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.

Willy Simon, Non-Executive Director

Willy Jules Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences plc.

John Brancaccio, Non-Executive Director 

Mr. Brancaccio, a retired CPA, is a financial executive with extensive international and domestic experience in pharmaceutical and biotechnology for privately and publicly held companies. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio is currently a director of Cardiff Oncology, Inc., Hepion Pharmaceuticals, Inc., Rasna Therapeutics, Inc., and Tiziana Life Sciences plc.

Bernard Denoyer, Non-Executive Director

Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc, from July 2008 until FDA approval and his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc. From October 2000 to December 2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc. Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a master’s Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honours from Columbia Business School in 1972 and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He is currently serving on the Board of Trustees for two not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc.

SCIENTIFIC ADVISORY BOARD

Napoleone Ferrara, MD, Board Member

Dr. Ferrara is a Professor at the University of California San Diego Medical Center and a member of The National Academy of Sciences and has received numerous prestigious awards, including the Lasker Award and the Breakthrough Prize in Life Sciences. His research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the discovery that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders. When Lucentis® (Ranibizumab) received FDA approval in late June 2006, the new macular degeneration drug was celebrated as a major medical breakthrough. Dr. Ferrara’s research also led to the development and approval of humanized anti-VEGF mAbs (Bevacizumab; Avastin®) for cancer treatment, with Avastin® being one of the bestselling cancer drugs over the last two decades. Lucentis® and Avastin® collectively achieved over $9 billion in sales last year.

Pedram Hamrah, MD, FRCS, FARVO, Board Member

Pedram Hamrah, MD is Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at New England Eye Center at Tufts Medical Center in Boston. Dr Hamrah’s research interests focus on corneal immunology and neuroscience, ocular imaging (immuno-imaging), ocular surface diseases and corneal neuropathic pain. He is currently on faculty at the departments of Ophthalmology and Bioengineering at Tufts University, where he is the director of clinical research and director of the Center for Translational Ocular Immunology. In addition, he is a faculty member at the immunology, neuroscience, and cell, molecular and developmental biology graduate programs at the Sackler School of Graduate Biomedical Sciences at Tufts. Throughout his career, he has focused on discovery, patient care and teaching. Dr. Hamrah currently serves on over a dozen editorial boards, is the associate editor for The Ocular Surface and TVST, section editor for Eye and assistant editor at Ocular Immunology and Inflammation.

Jay S. Pepose, MD, PhD, FARVO

Dr. Pepose, a specialist in refractive surgery and corneal and external diseases, is the founder and Medical Director of the Pepose Vision Institute and held the Bernard Becker Chair in Ophthalmology and Visual Sciences at Washington University School of Medicine in St. Louis. He is a consultant to numerous ophthalmic drug and device companies and serves as a Director and Chief Medical Advisor for Ocuphire Pharma. Dr. Pepose has been involved in over 40 clinical research trials, including registration trials for dry eye drugs, and has been the recipient of R-01 grant support from the National Eye Institute. He has served on the editorial boards of numerous prestigious journals, including the American Journal of Ophthalmology, Investigative Ophthalmology & Visual Science (IOVS), Cornea, and The Journal of Refractive Surgery and has over 200 peer reviewed publications. Dr. Pepose, an ARVO Gold Fellow, is a recipient of the Cogan Award from the Association for Research in Vision and Ophthalmology (ARVO) and the Life Achievement Honor Award from the American Academy of Ophthalmology. Dr. Pepose received an A.B. and M.A. in neurophysiology from Brandeis University and completed the M.D.-Ph.D. program at UCLA School of Medicine. He completed ophthalmology residency at the Wilmer Institute at the Johns Hopkins Medical Center and fellowship training at Georgetown University Medical Center

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA LLC FOR A ONE DAY OKYO AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: WISA) Profile

OUR NEW PROFILE IS:   (NASDAQ: WISA)

CASH AND CASH EQUIVALENTS WERE $5.3 MILLION AS OF MARCH 31, 2023

30+ BRANDS HAVE DESIGNED WISA TECHNOLOGIES INTO THEIR PRODUCTS

AS ANNOUNCED ON MAY 15, 2023, THE COMPANY EXPECTS ITS PLANNED ACQUISITION OF COMHEAR TO CLOSE IN THE THIRD QUARTER OF 2023 AND BE ACCRETIVE IN THE FOURTH QUARTER OF 2023. AS A RESULT, THE COMPANY IS GUIDING FOR FULL YEAR 2024 REVENUE IN THE RANGE OF $10 MILLION TO $15 MILLION

READ THE INVESTOR PRESENTATION HERE

_______________________________

Hello Everyone,

We have another company to you to research for Thursday’s session. 

This is a company that we have never profiled on this newsletter before.

Pull up WISA immediately.

WiSA Technologies (Nasdaq: WISA) develops, markets, and sells spatial audio wireless technology for smart devices and next-generation home entertainment systems. Its consortium—the WiSA Association—works with leading consumer electronics companies, technology providers, retailers, and industry partners to make spatial audio an experience that everyone can enjoy. The Company is headquartered in Beaverton, OR.

This one has some incredible catalysts driving it right now.

  • Strong IP position and significant patent coverage for immersive audio, with highly- differentiated multichannel wireless audio technology and existing implementations in premium audio brands
  • World-class premium technology ported to low-cost IoT chips to address mass market audio systems with software roadmap to address TAM of over 2 billion units
  • Establishment and management of the Wireless Speaker and Audio Association with interoperability specification, testing, and compliance standard
  • 30+ brands have designed WiSA technologies into their products, with expanded opportunities from Comhear’s products and target markets
  • Strong revenue growth from combined company for modules sales, audio systems sales, and licensing

Another MAJOR catalyst is the recent letter of intent signed by the company:

WISA TECHNOLOGIES SIGNS LETTER OF INTENT TO ACQUIRE COMHEAR, INC.

– Transaction expected to be accretive beginning in Q4 2023 –

– Complementary technology and solutions in immersive wireless audio –

modern living room showcasing interconnected wireless speakers

BEAVERTON, Ore.–(BUSINESS WIRE)– WiSA Technologies, Inc. (Nasdaq: WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, has signed a non-binding letter of intent to acquire Comhear, Inc. (Comhear), a developer of AI-enabled adaptive audio technology. The transaction is expected to close in the third quarter of 2023 and be accretive in the fourth quarter of 2023. 

Comhear’s proprietary adaptive filtering and beam steering system captures environmental room dynamics, processes data in real-time, and adjusts the audio output. The result is dynamic immersive audio that delivers personalized audio experiences in multiple applications, including home entertainment, gaming, retailing, and location-based entertainment.

“The synergy between the two companies is compelling on many levels, with similar business models driven by audio IP, licensing and module sales,” said Brett Moyer, CEO of WiSA. “We are targeting many of the same customers yet offer complementary solutions that address different use cases, providing WiSA’s sales team with more products to sell to our customers. We are both poised to penetrate the audio market through licensing our technologies. The acquisition of Comhear enhances WiSA’s position as a leader in immersive wireless audio technology, and we expect that the combined company will be well positioned to take market share in this growing market.”

“We expect the addition of Comhear to be accretive beginning in Q4 2023. As a result, we are guiding for full year 2024 revenue in the range of $10 million to $15 million,” added Moyer.

“With the shared vision to deliver next generation immersive audio, I am thrilled to join forces with WiSA and look forward to assuming the role of Chairman of the combined companies following the acquisition,” said Andy Arno, Chairman of Comhear. “Our strategy to license and sell IP-embedded audio modules perfectly overlaps with WiSA’s business model, and our technology is a natural fit in WiSA’s ecosystem. The combined company can leverage WiSA’s many established customer relationships with new products along with additional market segments that have been the focus of Comhear.”

Terms of the Proposed Transaction

Under the proposed acquisition, WiSA would acquire all shares of Comhear common stock in exchange for newly issued shares of WiSA common stock.

The board of directors of the combined company is expected to consist of seven members, four of whom will be appointed by WiSA, including Mr. Moyer, and three of whom will be appointed by Comhear, including Mr. Arno as chairman.

The letter of intent for the proposed transaction is non-binding, and the parties expect to enter into one or more definitive agreements with respect thereto in June 2023. Completion of the transaction is subject to, among other matters, the completion of due diligence, the negotiation of definitive agreements providing for the proposed transaction, and satisfaction of various conditions to be negotiated therein and customary for transactions of the type contemplated, including, but not limited to, receipt of regulatory approvals, the provision of an audit of Comhear’s financial statements, and board of director and WiSA shareholder approvals.

The company expects to issue a proxy statement seeking shareholder approval for the proposed transaction in July 2023. However, there can be no assurance that the parties will successfully negotiate and enter into definitive agreements regarding the proposed transaction, or that the proposed transaction will be completed as currently contemplated, or at all.

About Andrew Arno

Andrew Arno has over 30 years of experience handling a wide range of corporate and financial matters, including work as an investment banker and strategic advisor to emerging growth companies. Mr. Arno served as Chairman of C.E. Unterberg, Towbin, an investment bank, and currently serves on the boards of directors of Smith Micro Software, Inc. and Independa Inc., both software companies, Oncocyte Inc., a medical diagnostics company, as well as Comhear, Inc. Mr. Arno received a BS degree from George Washington University.

WISA TECHNOLOGY PRODUCTS ENABLE THE WORLD’S BEST BRANDS TO TRANSMIT AND RECEIVE ULTRA HIGH-QUALITY AUDIO—WIRELESSLY.

Superb quality, simple setup, and perfect synchronization are all traits that embody WiSA technology. And the brands that incorporate our technology into their products would settle for nothing less. Whether you’re developing TVs and sound systems or purchasing them for your home or business, WiSA ensures your wireless entertainment experience exceeds all expectations.

WISA LAUNCHES TWO NEW POWERFUL TOOLS FOR IMPLEMENTING, MANAGING AND TESTING WISA-ENABLED PRODUCTS

Tools provide customers with comprehensive support for developing and manufacturing WiSA E and WiSA DS designs for multichannel audio

BEAVERTON, Ore.–(BUSINESS WIRE)– WiSA Technologies, Inc. (NASDAQ: WISA), a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems, announces two new tools available to WiSA Technologies’ customers designed to streamline the development and manufacturing of WiSA E and WiSA DS implementations. The new WiSA Server, in combination with the new Product Support Engineering Tool (PEST), enables faster time-to-market as well as comprehensive management of testing and other aspects of the manufacturing process.

The WiSA Server and PEST tools join the latest version of the mobile app, launched in December 2022, as the latest software-based applications designed to support the WiSA ecosystem of users, product designers and manufacturers.

WiSA Server

Running on the product application processor, WiSA Server is a low-overhead software package that minimizes the time and effort required by customers to design systems using WiSA software. The WiSA Server Software Design Kit (SDK) provides high-level WiSA API commands via the product and mobile client interfaces and translates them into low-level I2C commands eliminating months from typical development cycles. Benefits include:

  • Accelerates product integration with simple, design-proven and tested API commands that significantly reduce code complexity and development time.
  • Ensures correct by-design interoperability across product families.
  • Supports Linux or RTOS operating system environments.
  • Automatically manages system push/pull notifications to all connected client devices. (e.g., volume notifications between mobile device, soundbar and speaker).

Product Support Engineering Tool (PEST)

In addition to managing and simplifying manufacturing module testing and programming, PEST provides efficiencies in test and manufacturing to make products operational and production ready. Benefits include:

  • Software programming support to update WiSA modules.
  • Tracking and traceability for product modules and final products.
  • Configuration support for WiSA modules, including device types, speaker locations, country code and manufacturing data.
  • Production test support for WiSA modules and final products including IOs, power, RF/Wi-Fi, audio, and pairing.

“We are doing everything possible to help our customers streamline their upfront development efforts and manage their manufacturing and testing of WiSA E and DS modules,” said Tony Parker, vice president of business development and strategy at WiSA Technologies. “The WiSA server dramatically helps customers reduce upfront development efforts, while the PEST tool provides powerful tracking and management of the final production process. Both add tremendous value to our customers as they develop and manufacture enabled products.”

For customers designing products with WiSA E or DS modules, WiSA Technologies offers a software design kit (SDK) for the WiSA Server and a manufacturing design kit (MDK) for the PEST tool. For more information about the WiSA Server and PEST tools.

Jul 25, 2023 7:00am EDT

WISA LAUNCHES TWO NEW POWERFUL TOOLS FOR IMPLEMENTING, MANAGING AND TESTING WISA-ENABLED PRODUCTS 

Jul 14, 2023 4:05pm EDT

WISA TECHNOLOGIES ALIGNS FINANCE LEADERSHIP TO FOCUS ON ANTICIPATED COMHEAR ACQUISITION 

Jun 15, 2023 9:00am EDT

SUNPLUS AND WISA TECHNOLOGIES PARTNER TO ENABLE COST-EFFECTIVE ATMOS SOUNDBAR APPLICATIONS UP TO 7.1.4 CONFIGURATIONS 

Jun 13, 2023 9:00am EDT

WISA TECHNOLOGIES BEGINS TAKING PRE-ORDERS FOR WISA E MULTICHANNEL AUDIO DEVELOPMENT KITS 

May 22, 2023 7:00am EDT

WISA TECHNOLOGIES, INC. TO PRESENT AT LD MICRO INVITATIONAL XIII 

May 17, 2023 7:00am EDT

HISENSE’S LATEST U7K AND U8K SERIES ULED TVS EARN WISA SOUNDSEND CERTIFICATION 

May 16, 2023 7:00am EDT

WISA TECHNOLOGIES REPORTS Q1 2023 RESULTS 

May 15, 2023 9:00am EDT

WISA TECHNOLOGIES SIGNS LETTER OF INTENT TO ACQUIRE COMHEAR, INC. 

May 10, 2023 8:55am EDT

WISA TECHNOLOGIES, INC. TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL AT 5:30 AM PACIFIC TIME | 8:30 AM EASTERN TIME ON MAY 16TH 

Apr 14, 2023 7:00am EDT

WISA TECHNOLOGIES PAYS OFF SENIOR SECURED CONVERTIBLE NOTE

Mar 24, 2023 7:00am EDT

WISA TECHNOLOGIES REGAINS COMPLIANCE WITH NASDAQ CONTINUED LISTING REQUIREMENTS 

Mar 16, 2023 6:00am EDT

WISA E ENABLES TVS TO TRANSMIT MULTICHANNEL AUDIO WITHOUT AN HDMI CABLE 

Mar 15, 2023 8:00pm EDT

WISA TECHNOLOGIES REPORTS Q4 AND FULL YEAR 2022 RESULTS 

Feb 28, 2023 7:00am EST

PYLON AUDIO’S JASPER LOUDSPEAKERS LINE EARNS WISA HT INTEROPERABILITY CERTIFICATION 

Feb 27, 2023 7:00am EST

WISA TECHNOLOGIES TO REPORT FOURTH QUARTER 2022 RESULTS AND HOST CONFERENCE CALL ON MARCH 16TH 

Feb 07, 2023 7:00am EST

MESANOVIC’S LATEST STUDIO MONITOR SPEAKER EARNS WISA HT INTEROPERABILITY CERTIFICATION 

Feb 03, 2023 1:35pm EST

WISA TECHNOLOGIES ANNOUNCES CLOSING OF $6.2 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT PRICED AT-THE-MARKET 

Feb 02, 2023 7:00am EST

WISA TECHNOLOGIES BEGINS SHIPPING WISA E MULTICHANNEL AUDIO DEVELOPMENT KITS TO INITIAL BETA CUSTOMERS 

Feb 01, 2023 8:35am EST

WISA TECHNOLOGIES ANNOUNCES PRICING OF $6.2 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT PRICED AT-THE-MARKET 

Jan 26, 2023 1:00pm EST

WISA TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT

MANAGEMENT TEAM

BRETT MOYER

Chief Executive Officer, President and Chairman

Brett Moyer is a founding member of the Company and has served as the President and Chief Executive Officer of the Company and as a member of its board of directors since August 2010. From August 2002 to July 2010, Mr. Moyer served as president and chief executive officer of Focus Enhancements, Inc., a developer and marketer of proprietary video technology. From February 1986 to May 1997, Mr. Moyer worked at Zenith Electronics Inc. a consumer electronic company, where he had most recently been the vice president and general manager of its Commercial Products Division. Since June 2016, Mr. Moyer has also served as a member of the board of directors of Alliant International University, a private university offering graduate study in psychology, education, business management, law and forensic studies, and bachelor’s degree programs in several fields. From 2003 to December 2015, he served on the board of directors of HotChalk, Inc., a developer of software for the educational market, and from March 2007 to September 2008, he was a member of the board of directors of NeoMagic Corporation, a developer of semiconductor chips and software that enable multimedia applications for handheld devices. Mr. Moyer received a Bachelor of Arts in Economics from Beloit College in Wisconsin and a Master’s of Business Administration with a concentration in finance and accounting from Thunderbird School of Global Management.

GEORGE OLIVA

Senior Vice President of Finance and Strategic Operations of the Company

George Oliva joined WiSA Technologies, Inc. in 2019 as the Chief Financial Officer.  Mr. Oliva has over 25 years as a senior finance professional, with a background in corporate finance, treasury, financial planning and analysis, manufacturing cost, international tax, and strategic planning. Most recently, he was a partner with Hardesty LLC, a national executive services firm. Mr. Oliva has held several CFO positions. At Penguin Computing, he orchestrated a turn-around. At StorCard, he guided the early-stage company in capital financing and more. At StreamLogic, a public company doing business as Hammer Storage Solutions, he navigated its going-private transaction. Prior to serving in such roles, Mr. Oliva was responsible for financial planning and analysis and operational support as the operations controller for Conner Peripherals and Read-Rite Corporation.  Mr. Oliva began his career in auditing with Arthur Andersen & Co. He earned a degree in Business Administration from U.C. Berkeley with a dual emphasis in Accounting and Finance.

GARY WILLIAMS

Chief Accounting Officer and Vice President of Finance

Gary Williams has served as Chief Accounting Officer since September 9, 2019 and as Vice President of Finance since the Company’s founding in August 2010. Mr. Williams previously served as Secretary and Chief Financial Officer since the Company’s founding in August 2010 until September 9, 2019. In addition, Mr. Williams served as the Chief Financial Officer of Quantum3D, Inc., a training and simulation technology company, from November 2012 to September 2016. Prior to joining the Company, Mr. Williams served as secretary, vice president of finance and chief financial officer of Focus Enhancements Inc., a developer and marketer of proprietary video technology, from January 2001 to July 2010, when the videography and semiconductor businesses of the company were purchased by VITEC Multimedia, Inc. and the Company, respectively. Mr. Williams served as controller, vice president of finance, chief financial officer and secretary of Videonics Inc., a publicly traded company in the consumer electronics business, from February 1995 to January 2001, when Videonics merged with Focus Enhancements, Inc. From July 1994 to January 1995, Mr. Williams served as controller for Western Micro Technology, a publicly traded company in the electronics distribution business. From January 1990 to June 1994, Mr. Williams worked in public accounting for Coopers & Lybrand LLP. Mr. Williams is a certified public accountant, inactive, and received a Bachelor’s Degree in Business Administration, with an emphasis in Accounting, from San Diego State University.

ED GREEN

Vice President of Operations

Ed Green is a founding member of WiSA Technologies, Inc. serving as Vice President of Operations. Currently reporting to Mr. Green are the Production & Test Engineering, Quality and Reliability, and the IT departments. Prior to joining WiSA Technologies, Inc., Mr. Green held several positions at Network Elements Inc., Beaverton, OR. Most recently, Mr. Green was Product Line Manager for NEI’s 10 Gigabit Ethernet group. Mr. Green was the driving force behind NEI’s XENPAK, X2 and XFP programs. Over Mr. Green’s four year career at NEI, he was responsible for all design-for-test (DFT) on NEI’s 10Gb/s SERDES IC, and validation of NEI’s first multi-protocol ASIC. In 2000, Mr. Green served as Chief Operating Officer for Sunhoo.com based in Shanghai, China. There, Mr. Green was responsible for the development and implementation of the company’s business model and plan for a financial web portal in China. For the seven years prior to Sunhoo.com, Mr. Green operated a small chain of family entertainment centers. Mr. Green was responsible for all design, construction, implementation, management, and financial and corporate matters involving the company’s five stores and 70 employees. Mr. Green earned his BS in Electrical Engineering in 1983, and his MBA in Accounting in 2004.

JAMES CHENG

Vice President of Worldwide Sales

Cheng has more than 15 years of experience leading international business development for Silicon Valley tech brands with extensive experience in ecosystem and partner development. Prior to joining WiSA Technologies, Inc., he was VP marketing and business development at Amlogic, Inc., a global fabless SoC company that provides open platform solutions for multimedia consumer devices. Prior, Cheng was director of strategic accounts at GoerTeck, Inc. and senior director of business development at Marvell Semiconductor where he was responsible for developing Google 1st party brand and ecosystem partner business. He holds a B.E. degree in electrical engineering from Tamkang University, a PhD in electrical engineering from Stony Brook University and an MBA from NYU Stern School of Business.

KEITH GREENEY

Vice President of Engineering

Keith Greeney is a founding member of WiSA Technologies, Inc. serving as Vice President of Engineering. Mr. Greeney manages five groups within WiSA Technologies, Inc.; Research and Development, System Testing, FW Development, Application Development, and Reference Design Development. Mr. Greeney has over 25 years of experience in Firmware, Hardware, Digital Signal Processing (DSP) and ASIC design. He began his career as a system configuration manager at Applied Research Laboratories while pursuing a BSEE from the University of Texas at Austin. Prior to joining WiSA Technologies, Inc., Mr. Greeney was a key contributor to Tektronix’ Federal Systems, the group responsible for developing the world’s first real-time digital spectrum analyzer, the Tektronix 3052. Along with algorithm design and design-for-test (DFT) responsibilities for the 3052, Mr. Greeney developed and implemented the production line. At WiSA Technologies, Inc., he is responsible for the successful design and implementation of over 10 ASICs ranging from scan converters, alpha blenders, UWB and Wireless Audio for key customers including Bang & Olufsen, Intel, and Microsoft Xbox.

TONY OSTROM

President WiSA

Tony Ostrom is the President of the Wireless Audio and Speaker Association (WiSA). His 25-year career in the consumer electronics industry has been focused on product planning and development, consumer research, technology integration, go-to-market planning, marketing, training and sales. Prior to joining WiSA Tony was the Vice President of Product Development at Klipsch Group where he managed multiple categories including Wireless Home Theater, Wireless Distributed Audio, Bluetooth and Powered Audio Solutions. Prior to Klipsch, Tony played key roles in the global launches of Powermat Wireless Charging as well as the House of Marley audio and lifestyle brand. Tony was Director of Product Development and Marketing at Klipsch Group where he drove the Mass Retail and Personal Audio categories and started his career at JL Audio where he was a Technical Director. Tony has a BA in Music Engineering and a Minor in Physics from Ball State University, Muncie Indiana.

TONY PARKER

Vice President of Business Development and Strategy

Tony Parker is a founding member of WiSA Technologies, Inc. serving as Vice President of Business Development and Strategy. Mr. Parker has 25 years of experience in semiconductor marketing leadership, with extensive expertise in wireless markets, including WiFi and UWB. Prior to joining WiSA Technologies, Inc., he was director of marketing with Cirrus Logic for ARM system-on-chip solutions and audio DSP products for decoding and post processing of sound effects targeting AVR, DTV and automotive applications. Prior to that, he was senior manager of corporate strategy and technology for Agere Systems, directing and leveraging company-wide resources across multiple product families including data networking, mobile, and storage businesses. Parker also has a proven track record of developing and delivering the right products to semiconductor markets while working in key product management and marketing management positions at Texas Instruments, AT&T, and Lucent Technologies. Mr. Parker holds a BS degree in Electrical Engineering from Bradley University, Peoria Illinois, as well as an MBA degree from Syracuse University, Syracuse, NY.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY WISA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NEW PROFILE! NASDAQ: BCAN

_______

Sponsored on behalf of BYND Cannasoft

OUR NEW PROFILE IS:   (NASDAQ: BCAN)

THE EZ-G DEVICE REPRESENTED A $28 MILLION TRANSACTION

BCAN IS AN EARLY PLAYER IN THE AI-POWERED ADULT TOY MARKET 

INSIDERS OWN OVER 64% OF THIS ONE!!

BCAN HAS LESS THAN 9M SHARES AVAILABLE IN ITS PUBLIC FLOAT

 CHECK OUT THE INVESTOR DECK HERE

_____________________

Hello Everyone,

We have another profile with several catalysts in play that we want you to take a look at for Monday’s session.

We are seeing activity starting to really pick up on this one.

Pull up BCAN immediately. 

In the adult toy industry, AI and wearable sex toys have the potential to revolutionize the market, which is expected to be worth $62.32 billion by 2030. (9)

One company to keep an eye on in this space in the AI-power sex toy market is BYND Cannasoft Enterprises Inc. (BCAN).

This one has a few catalysts to look at:

HIGHER POTENTIAL FOR GROWTH:

In general, micro-cap companies have market capitalizations of between $50 million and $300 million. (17) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (17) As of 7/19/23, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has a market cap of approximately $51.49M according to MarketWatch.com. (18)

EXTREMELY LOW FLOAT:

Stocks with low floats have the potential to present significant swings. (4) BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has less than 9M shares available in its public float according to MarketWatch.com. (19)

HUGE MARKET:

The global sensual wellness market is projected to be worth $125B by 2026 with the intimate technology market expected to reach $62.32B by 2030, presenting a significant opportunity for a company like BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) to capture a portion of this market with its AI-powered adult toy technology. (2) (1)

INTELLECTUAL PROPERTY:

Positive news on patent applications for BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) could prove to be a significant catalyst in 2023. The company’s recently filed a PCT application for their EZ-G device, which uses AI and sensors to provide a more sensual experience. (1) If positive news on the patent application comes out, it could lead to increased confidence and significant upside potential.

EARLY MOVER ADVANTAGE:

As an early mover in the AI-powered adult toy market, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) has the potential to establish itself as a leading player in the industry, providing a competitive edge over later entrants. (1)

STRONG INSIDER OWNERSHIP:

High insider ownership typically signals confidence in a company’s prospects and ownership in its shares. (6) BYND Cannasoft Enterprises Inc. (BCAN) insiders own approximately 64.09% of the shares as of 7/19/2023 according to Finviz.com. (5)

_____

As of 7/19/23, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has less than 9M shares available in its public float according to MarketWatch.com. (19)

Not to mention, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) could have a higher potential for growth given their status in the market as a micro-cap.

In general, micro-cap companies have market capitalizations of between $50 million and $300 million. (17) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly.(17)

As of 7/19/23, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has a market cap of approximately $51.49M according to MarketWatch.com. (18)

Overall, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has several positive catalysts, such as its potential for growth and low public float, making it an attractive option for those looking to take advantage of swings with significant potential.

Maybe that’s why BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) insiders are holding onto so many shares according to Finviz. (5)

Strong insider ownership can be an indication of a company’s health and long-term potential. When insiders own a significant percentage of a company’s shares, they have a vested interest in the company’s success, which can align their interests with those of other shareholders.

High insider ownership typically signals that insiders believe in the company’s future prospects and have confidence in its management team.

BYND Cannasoft Enterprises Inc. (BCAN) has over 64% insider ownership, (5)mv which is a strong indication of confidence in the company’s future prospects.

This level of insider ownership could be a sign that the management team has a significant stake in the company’s success. When insiders own a large percentage of a company’s shares, it can also indicate that they are committed to the company for the long term, as they have a significant financial stake in its future performance.

The market often views high insider ownership as a positive signal, as it indicates that insiders are financially interested in the company’s success.

This can also provide shareholders with greater transparency into the company’s operations and decision-making processes, as insiders are more likely to share information with shareholders who have a vested interest in the company’s success.

BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN) (CSE:BYND) ENTERS $62 BILLION MARKET WITH FILING OF US PROVISIONAL PATENT APPLICATION AND FULL SCALE PCT APPLICATION FOR ITS AI-CONNECTED EZ-G DEVICE (1)

3

Image Source (11)

On January 17, 2023, BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND)announced that in addition to the US Provisional Patent Application with serial number 63/297,009 that was filed on January 6, 2022, covering the monitoring and controlling aspects of its EZ-G device, the company filed a full-scale PCT application on January 5, 2023, under serial number PCT/IL2023/050016. (1)

The PCT application is based on BYND Cannasoft’s prototype of the EZ-G device that is currently under development and its operational aspects as a learning adult device. The PCT application further claims priority from the US Provisional application and covers an adult device with a structure and one or more moving and vibrating elements. (1)

In addition to potentially treating annoying phenomena in the female reproductive system, the EZ-G device includes technological advancements to provide a more sensual experience. The EZ-G device prototype uses sensors like a pressure sensor, temperature sensor, conductivity sensor, and heart rate sensor to determine what specifically enhances the users’ gratification.

4

Image Source (12)

The EZ-G device uses artificial intelligence (AI) to transmit and receive data from the device’s sensors on conditions of the user’s organs, such as moisture levels and pressure variations due to muscle contraction. 

The EZ-G prototype includes a Bluetooth component for controlling the adult device via an app installed on a smartphone or other portable device to collect user information about preferences and generate custom programs.

The data collected from the sensors is uploaded to the secured cloud, where it is combined with other antonymic user preferences, including the actual duration of operation of the adult device, lubrication level, and the ideal vibration level.

This data enables the device to enhance the user’s overall experience, leading to heightened sensations and a more fulfilling encounter. By learning and adapting to the user’s preferences, the EZ-G device optimizes its performance to provide maximum sensual satisfaction.

Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said

“The EZ-G device has evolved to provide treatment relief from sensual and mental problems, including the ability to have intercourse as it relates to anxiety and physical pain. The device is capable of enhancing sensual gratification and reducing Dyspareunia by dispensing low concentrations of C-B-D oil lubricant in a controlled manner. It could be configured to use disposable capsules that include the C-B-D lubricant, which could be dispensed in accordance with data collected by the sensors. The sale of the disposable capsules containing the C-B-D lubricant would provide BYND Cannasoft with a revenue model much like the razor and the razor blade.” (1)

BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN)(CSE:BYND) EXPANDS FOOTHOLD IN THE MULTIBILLION-DOLLAR SEXTECH INDUSTRY WITH ITS NEXT AI-BASED TECHNOLOGY PATENT (23)

This image has an empty alt attribute; its file name is img-bynd-new-2.png
Image Source (21)

BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) is making its mark in the multibillion-dollar Sextech Industry as its subsidiary, Zigi Carmel Initiatives & Investments LTD., files a U.S. provisional patent application for an innovative smart female treatment device. This new device, powered by artificial intelligence (AI), aims to treat specific phenomena related to female sexual organs. (23)

The device leverages AI and machine learning algorithms to control its operational parameters based on the user’s physiological data. Its functions include stimulation of sexual organs according to user preferences, as well as real-time monitoring of user satisfaction levels through integrated sensors. The patent application covers an AI system that stores user preference data, allowing it to learn general and current operation preferences. By collecting data on responses to different operation parameters, the AI fine-tunes its operation to provide a personalized and optimized experience for each user.

In addition to its medical applications, BYND Cannasoft recognizes the potential of this AI-based device as a sex toy. The patented technology offers the ability to enhance the interaction between humans and machines, collecting data on user response to stimulation patterns, determining lubricant dispensing rates, and even identifying sexual climax using AI and machine learning techniques. The device ensures a natural and controlled experience based on real-time data and user preferences. It also includes a communication component that utilizes sensor data to create customized programs and upload data to the cloud.

This image has an empty alt attribute; its file name is img-bynd-new-3.png
Image Source (22)

Yftah Ben Yaackov, CEO and Director of BYND Cannasoft, highlighted the significance of the AI-based device, especially in a time where companies are increasingly focusing on automated and personalized customer connections. Real-time technologies and generative AI are shaping consumer behavior and influencing purchasing decisions. BYND Cannasoft plans to secure the final registration of its patents, establish a robust marketing and sales system for both the AI-based device and the EZ-G device, and cater to both B2B and B2C sales.
BYND Cannasoft Enterprises is poised to revolutionize the Sextech industry with its groundbreaking AI-based devices, bringing innovation, personalization, and enhanced user experiences to the forefront. (23)

MAJOR MILESTONE: BYND CANNASOFT ENTERPRISES (NASDAQ: BCAN) (CSE: BYND) COMPLETES LAB TESTING PHASE FOR INNOVATIVE EZ-G DEVICE (24)

IMG-BYND-NEW-4
Image Source (25)

BYND Cannasoft Enterprises (NASDAQ: BCAN) (CSE: BYND) has reached a significant milestone with the successful completion of the laboratory testing phase for its groundbreaking EZ-G device. The company, based in Ashkelon, Israel, and Vancouver, British Columbia, announced the accomplishment, highlighting the optimization of various sensors within the device. The EZ-G, a therapeutic solution powered by AI and machine learning, has shown promising potential in delivering low concentrations of C-B-D oils, including hemp seed oil and other natural oils, to address specific women’s health issues. (24)

During the laboratory testing phase, BYND Cannasoft conducted comprehensive experiments as part of the EZ-G device’s prototype development. The focus was on evaluating the functionality and performance of the integrated sensors, which detect indicators such as temperature, heart rate, contractions, and fluids. By collecting and analyzing data through accompanying software, the company utilized machine learning technology to optimize the device’s usage for users.

This milestone marks a significant achievement in the development of the EZ-G device, particularly in the successful functionality of its primary sensor, the capacitive sensor. The sensor has demonstrated its ability to accurately detect the presence or absence of liquid within the device, specifically identifying changes in fluid volume in the vagina. As a result, the device can regulate the flow of oil or lubricating fluid during operation without the need for manual intervention from the user.

With positive results from the laboratory testing phase, BYND Cannasoft is now poised to finalize the EZ-G prototype model and progress to the next phase of development: human trials involving focus groups of women across different age groups.

Yftah Ben Yaackov, CEO and Director of BYND Cannasoft, expressed enthusiasm about the successful completion of the laboratory testing phase for the EZ-G device. He emphasized the company’s commitment to leveraging advanced technology to enhance women’s health. Moving forward with human trials, Ben Yaackov believes the EZ-G device has the potential to revolutionize therapeutic approaches for women’s health issues.

BYND Cannasoft remains dedicated to ensuring that the EZ-G device meets the highest standards of safety, efficacy, and usability. Through continued research and development efforts, the company aims to make a meaningful contribution to women’s well-being by providing an innovative solution for targeted health concerns. (24)

BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN)(CSE:BYND)

TRENDS IN THE MARKET

5

Image Source (13)

Key Takeaways: (13)

  • Consumer demand is surging: There were 36m+ connected “intimate technology” devices in use globally last year, representing 87% YoY growth.
  • The market for connected devices alone is expected to more than double over the next 5 years to reach $9B.
  • Intimate Tech goes far beyond toys. It’s set to disrupt all areas of the sensual wellness space, from health to education.
  • The wider industry of sensual wellness, which is now worth $62B, is forecast to exceed $125B by 2026.
  • The sensual-health movement is driving change; industry veterans believe we are on the cusp of a surge in funding.
  • The US Intimate Technology market is still largely offline, leading to attractive ecommerce opportunities.

BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN)(CSE:BYND)

LET’S MEET THE TEAM LEADING THIS LITTLE-KNOWN “AI STOCK” INTO 2023 AND BEYOND. (14)

6

Image Source (15)

As a relatively new player in the adult toy market, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) has the advantage of being an early mover and can establish itself as a leader in the space.

Another advantage of BYND Cannasoft Enterprises Inc. is its experienced leadership team. The company is led by a team of experienced executives who have a proven track record of success in multiple industries. (14)

CLIENTS

This image has an empty alt attribute; its file name is Screen-Shot-2022-10-26-at-8.44.39-PM-300x179.png

MANAGEMENT

This image has an empty alt attribute; its file name is MotiMaram.bd4764a4d48c0b5f633e.jpg

MOTI MARAM

President and Director

In 1986, together with a partner company, he founded a computer company that mainly provided services to EXATEC-compliant IBM AS 400 computers and subsequently sales and service to the first PCs in the world. After identifying a need for CRM and ERP software, Maram and his partner, Avner Tal, established a software company that manufactures CRM and ERP management software called BENEFIT in 2000.

This image has an empty alt attribute; its file name is HaroldWolkin.257e6c012b85a0287ce7.jpg

HAROLD WOLKIN

Harold is a retired, former Investment Banker and Financial Analyst with over 40 years of business experience. An advisor to Chief Executive Officers and Board of Directors of both public and private companies. Strong financial expertise, a Chartered Financial Analyst (CFA) and member of the Institute of Corporate Directors.

This image has an empty alt attribute; its file name is YiftahBenYaackov.073052fdeac73631b6af.jpg

YFTAH BEN YAACKOV

CEO and Director

Professional lawyer since 2004. Specialized in real estate related issues on all aspects of it including real estate corporations, complex sales transactions, real estate unions, real estate taxation. Notary License holder since 2014. Managed large projects of tens of thousands Square meters for a total amount of above 400 million NIS. At the last 5 years yftah has assembled the business activity of 2 of the largest medical cannabis company’s in Israel and has an enormous experience and knowledge in this field.

This image has an empty alt attribute; its file name is StefaniaSzabo.baef6c1638b6996607d4.jpg

DR. STEFÁNIA SZABÓ

Director

Stefánia is the Vice President of Pace Law Firm and Director of International Relations at Pace Global Advantage in Toronto, Canada. She is a former diplomat, a charismatic government services, management and public relations professional with 25 years of progressive experience. She is an international lawyer by profession, and serves as member of the executive committee of the Canada-Israel Chamber of Commerce.

This image has an empty alt attribute; its file name is AvnerTal.89901801ac3497ebc54c.jpg

AVNER TAL

VP Sales & Marketing, CTO and Director

Technology director of Beyond Solution Company. I studied electronics and control. I served in the Navy and I was in the team that implemented and developed the technology and even carried out the experiments that included “smart” missiles. Joined Moti to established a computer company that supported Exatech computers and its innovative network.

NEWS

  • 
  • GlobeNewswire•2 days agoBYND CANNASOFT CLOSES US$2.6 MILLION UNDERWRITTEN PUBLIC OFFERINGASHKELON, Israel and VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately US$2.6 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 1,733,334 common shares at a price to the public of
  • GlobeNewswire•4 days agoBYND CANNASOFT ANNOUNCES PRICING OF US$2.6 MILLION UNDERWRITTEN PUBLIC OFFERINGASHKELON, Israel and VANCOUVER, British Columbia, July 17, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately US$2.6 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consists of 1,733,334 common shares at a price to th
  • GlobeNewswire•7 days agoBYND CANNASOFT ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERINGASHKELON, Israel and VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, o
  • GlobeNewswire•11 days agoBYND CANNASOFT ANNOUNCES SUCCESSFUL COMPLETION OF LABORATORY TESTING PHASE FOR EZ-G DEVICE OPTIMIZATIONASHKELON, Israel and VANCOUVER, British Columbia, July 10, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today the successful completion of the laboratory testing phase aimed at optimizing the various sensors in its innovative EZ-G device. The EZ-G device, a therapeutic solution utilizing AI and machine learning, has shown promise in releasing low concentrations of CBD oils, including hemp seed oil and other natu
  • GlobeNewswire•3 months agoBYND Cannasoft Subsidiary Zigi Carmel Initiatives & Investments LTD. filed U.S. Provisional Patent Application 63461609 on April 25, 2023 covering the mechanical structure, operation, and controlling aspects of a treatment device monitored by sensors and capable of stimulating the male sexual organs based on user preferences ASHKELON, Israel and VANCOUVER, British Columbia, April 27, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Com
  • GlobeNewswire•3 months agoBYND Cannasoft Subsidiary Zigi Carmel Initiatives & Investments LTD. received a positive opinion from the examiner of the PCT for its method that enables its AI-based device to identify a level of satisfaction according to parameters received from the device sensorsASHKELON, Israel and VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today it has received a positive opinion fro
  • GlobeNewswire•4 months agoPlans to formulate proprietary CBD oil and brand through a licensed grower in Israel for distribution outside of Israel in its AI based device and EZ-G deviceVANCOUVER, British Columbia and ASHKELON, Israel, March 14, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced plans to formulate a proprietary CBD oil and brand through a licensed grower in Israel for distribution outside of Israel for its new artificial i
  • GlobeNewswire•4 months ago

SINCERELY,

This image has an empty alt attribute; its file name is 1H_UjaaG1TIUmUkjvfYqGDl6vqBx2tZG2WEa7ZwrHYjmo7QHGtA0npnUb5G7UzfVAincbmC42pwbZUFihT8n05yCoMTa5mqO7b43-k-xDIPXBE9yE3StSIPSKzcoJf87Kpcu5kJ7kUL9Et8M_7rhbF57J5Y6_3W46NGaYg=s0-d-e1-ft

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY ONE THOUSAND USD BY A THIRD PARTY, TD MEDIA LLC FOR A ONE DAY BCAN AWARENESS CAMPAIGN. PURSUANT TO AGREEMENT BETWEEN TD MEDIA LLC AND DEDICATED INVESTORS LLC. ON BEHALF OF BYND CANNASOFT, DEDICATED INVESTORS HAS BEEN HIRED FOR A PERIOD BEGINNING ON 7/24/2023 AND ENDING ON 7/24/2023. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Sources:
Source 1: https://finance.yahoo.com/news/israeli-cannabis-technology-company-bynd-133000351.html
Source 2: https://trends.co/articles/lets-talk-about-sextech/
Source 3: https://www.barchart.com/stocks/quotes/BCAN/price-history/historical
Source 4: https://stockstotrade.com/low-float-stocks/
Source 5: https://finviz.com/quote.ashx?t=BCAN&p=d
Source 6: https://www.investopedia.com/articles/stocks/05/042605.asp
Source 7: https://www.precedenceresearch.com/artificial-intelligence-market
Source 8: https://schrts.co/DxgEQfKp
Source 9: https://www.businesswire.com/news/home/20220525005765/en/Sex-Toys-Market-Analysis-Report-2022-A-62.32-Billion-Market-by-2030
Source 10: https://www.smartcompany.com.au/startupsmart/startupsmart-technology/sextech-industry-players-making-waves/
Source 11: https://cannasoft-crm.com/
Source 12: https://media.springernature.com/w580h326/nature-cms/uploads/collections/AI_and_machine_learning-00afb90f3d21234fd0f207243f60aa8e.jpg
Source 13: https://trends.co/articles/lets-talk-about-sextech/
Source 14: https://cannasoft-crm.com/#/team
Source 15: https://www.cio.com/wp-content/uploads/2023/02/ai_artificial-intelligence_circuit-board_circuitry_mother-board_nodes_computer-chips-100777423-orig-2.jpg?quality=50&strip=all&w=1024
Source 16: https://finance.yahoo.com/news/u-patent-filed-bynd-cannasoft-123000701.html
Source 17: https://www.carboncollective.co/sustainable-investing/microcap-stock
Source 18: https://www.marketwatch.com/investing/stock/bcan?mod=search_symbol
Source 19: https://schrts.co/EejiCgQm
Source 20: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 21: https://techmonitor.ai/wp-content/uploads/sites/4/2022/09/shutterstock_1698736867.jpg
Source 22: https://images.idgesg.net/images/article/2020/07/virtual_brain_wired_with_technology_connections_artificial_intelligence_machine_learning_mental_health_and_technology_by_just_super_gettyimages-1149178089_2400x1600-100851295-large.jpg?auto=webp&quality=85,70
Source 23: https://finance.yahoo.com/news/u-patent-filed-ai-based-133000603.html
Source 24: https://finance.yahoo.com/news/bynd-cannasoft-announces-successful-completion-123000599.html
Source 25: https://global-uploads.webflow.com/60789a45beb6eb469601750e/61ef529d00ac80642bf725bb_pexels-photo-2280571.jpeg



Categories
Report

(Nasdaq: AGBA) Profile

OUR NEW PROFILE IS:   (NASDAQ: AGBA)

REVENUE FOR Q1 2023 OF USD$11.1M, UP 533% ON THE SAME PERIOD IN 2022

AGBA GROUP EXPECTED TO ACHIEVE APPROXIMATELY US$160 MILLION IN REVENUE FOR 2023 AFTER POSTING $30+ MILLION IN 2022.  THIS WOULD BE A 500%+ INCREASE

LARGEST INDEPENDENT FINANCIAL ADVISOR IN HONG KONG & 3RD LARGEST HEALTHCARE BRAND IN HONG KONG

READ THE INVESTOR PRESENTATION HERE

Hello Everyone,

Our last profile did not disappoint.  It gapped up and opened at .90 on Monday after closing at .82 on Friday.  During Tuesday’s session it exploded to 1.05 for a 15% move overnight off of yesterday’s open.

We have another one that we want you to look at for Wednesday’s trading.

Pull up AGBA Immediately.

The Chinese insurance industry has experienced rapid expansion over the past decade.In addition to steadily increasing demand, two major supply-side trends have encouraged the development of the industry: (1) under the World Trade Organization (WTO) framework, the Chinese government lowered entry barriers to foreign insurers, allowing them to establish joint-venture insurance firms in China; and (2) domestic insurers strengthened themselves through initial public offerings and other market developments.
AGBA, with 2,000 financial advisors, over 200,000 customers, and roughly $200 million in normalized revenue, is the regional giant with tremendous advantage over the region to supplement the populations needs.

Their extensive partnership network includes Cigna, Zurich, BOC Life, BlackRock, J.P. Morgan, Allianz, Invesco, Fidelity International, Sun Life, MetLife, Franklin Templeton Investments, Value Partners Group, Schroders, Amundi, FWD Insurance, and many more.

  • In 2019, China became the world’s second largest insurance market with annual premium income hitting USD0.63 trillion dollars, but insurance penetration is still far behind those of developed markets
  • There are now more options for foreign insurers to enter or re-enter China and capitalize on the opportunities presented by new opening-up policies
  • Competition from foreign insurers will push domestic insurers to learn from global best practices and shape a better insurance industry

AGBA is a leading one-stop financial supermarket based in Hong Kong offering the broadest set of financial and healthcare products in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) through a tech-led ecosystem, enabling clients to unlock the choice that best suits their needs.

Trusted by over 400,000 individual and corporate customers, the Group focuses on four market-leading businesses: Platform Business, Distribution Business, Healthcare Business, and Fintech Business.

Established in 1993, the company became a publicly listed company on NASDAQ in November 2022. In 2019, the Group started implementing a strategy to separate its legacy broker-dealer business into a platform business and a distribution business. Today, AGBA offers unique product and service offerings:

– B2C: market leading portfolio of wealth and health products

– B2B: tech-enabled broker management platform for advisors

WHAT MAKES AGBA UNIQUE?

Immediate access to GBA integration and expansion capturing huge organic and inorganic growth opportunities (GBA = USD17 trillion GDP = 13% of China’s economy)

Enable wealth and health with ease by offering the broadest portfolio of financial and healthcare products and services through a wide range of internal and external distribution channels (including the largest team in HK of licensed professionals.

Innovative, tech-led ecosystem backed by an in-house proprietary system, integrating innovative financial and healthcare solutions into one platform, enabling distributors and clients to unlock the best choice and benefits.

Regulatory compliance with national and provisional operating licenses since 2006 and proven operational excellence and credibility under stringent regulatory regimes.

Top-notch leaders with deep industry expertise and impeccable credentials across Platform, Distribution, Healthcare, and Fintech business for over 20 years.

The Group now comprises of four market-leading businesses: 

1. Platform Business: The Group operates as a “financial supermarket” offering over 1,800 financial products to a large universe of retail and corporate customers.

2. Distribution Business: The Group’s powerful financial advisor business is the largest in the market, it engages in the personal financial advisory (“IFA”) business (including advising and sales of a full range of financial services products including long-term life insurance, savings and mortgages), with additional internal and external channels being developed and added.

3. Healthcare Business: The Group is a minority investor in, and operates, one of the largest healthcare management organizations in the Hong Kong and Macau region, with over 800 doctors in its network. Established in 1979, this business

4. Fintech Business: The Group has an ensemble of leading FinTech assets and businesses in Europe and Hong Kong. In addition to financial gains, the Group also derives substantial knowledge transfers from its investee companies, supporting the development and growth of the Group’s new business models.

AGBA GROUP HOLDING LIMITED (NASDAQ: ‘AGBA’) EXPECTS HIGH GROWTH TO EXCEED US$160M REVENUE WITH ITS MARKET-LEADING FRANCHISE

HONG KONG, May 1, 2023 /PRNewswire/ — AGBA Group Holding Limited (Nasdaq: “AGBA”), a leading one-stop financial supermarket in Hong Kong makes certain clarifications to their projected revenue, franchise strength, and engagement with investors and analysts.

Revenue:

As previously stated in the disclosure of “AGBA Group Financial Projections 2023-2027 and Valuation Presentation” released on April 14, 2023, AGBA Group expected to achieve approximately US$160 million in revenue for 2023, which is equivalent to a 533% growth from the full year revenue in 2022 as reported in the Form 10-K for the fiscal year ended December 31, 2022. During the three years under COVID-19 impact from 2020 to 2022, the group maintained a solid revenue track record between US$69mto US$88m per annum.  AGBA expects that the current China’s border reopening will spur a new wave of revenue growth in 2023 and 2024.  Further disclosures and explanations can be found in the “AGBA Group Financial Projections 2023-2027 and Valuation Presentation” at www.agba.com/ir.

Franchise Strength:

AGBA Group is situated in AGBA Tower in Wan Chai, a prominent business district in Hong Kong, serving as the headquarters of its core financial services business. With over 30 years of track record and a workforce of 2,600+ colleagues, the Group specializes in selling life insurance policies and mutual funds, making AGBA one of the largest and most established companies in the region.

AGBA GROUP HOLDING LIMITED (NASDAQ: ‘AGBA’) ANNOUNCES Q1 2023 RESULTS AND SEES TREMENDOUS OPPORTUNITIES FOR GROWTH AS MAINLAND CHINA AND HONG KONG REBOUND

  • Revenue for Q1 2023 of USD$11.1m, up 533% on the same period in 2022

HONG KONG, May 15, 2023 /PRNewswire/ — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, today published its financial results for the first quarter of 2023. The Group reported revenue of USD$11.1m, which is 5 times higher compared to Q1 2022.

During March 2023, the Group recorded the highest level of new business applications in the past three years. AGBA expects strong growth to continue throughout the remaining quarters of the year. The Group’s optimistic outlook is driven by Hong Kong’seconomic rebound, marked by the reopening of borders, the return of mainland visitors, and strong domestic demand.

Throughout the first quarter, AGBA continued its tech deployment with ongoing enhancements to its client and advisor tools, further improving our customer journeys. In its Platform Business, the Group onboarded 10 new insurance partners and released more than 170 new insurance and investment products – offering over 2,000 financial products in total. In its Distribution Business, the Group signed up three new distribution partners using AGBA’s platform business, OnePlatform, as well as one of the large local banks. It also kickstarted a new incubation distribution channel, partnering with smaller adviser teams.

In April 2023, the Group continued its international expansion drive by announcing an agreement to acquire Sony Life Financial Advisers Pte Ltd, a licensed financial adviser and insurance broker in Singapore. This acquisition marks a key milestone for AGBA to drive its expansion beyond the Greater Bay Area into Southeast Asia.

Also in April 2023, AGBA has in place a program to repurchase up to 1 million shares (up to a maximum value of USD 10 million). The share repurchase program reflects AGBA’s commitment to returning value to its shareholders, while maintaining the financial flexibility to invest in growth opportunities.

Wing-Fai Ng, Group President, AGBA Group Holding Limited said, “Hong Kong’s rebound and the return of mainland visitors, coupled with our commitment to innovation and expansion, sets the stage for an exciting period of growth and prosperity for AGBA. We expect to see continued growth, especially during the second half of this year. We remain committed to investing in our businesses, creating innovative technologies and expanding our product offerings to stay ahead of the curve and capitalize on Hong Kong’s unique opportunities. Year 2023 is going to an exciting year for all of us at AGBA.”

For a detailed analysis of our Q1 2023 financial results and future outlook, please refer to the accompanying investor presentation available on our website at  www.agba.com/ir

AGBA GROUP HOLDING LIMITED (NASDAQ: ‘AGBA’) ANNOUNCES SHARE REPURCHASE PROGRAM

HONG KONG, April 18, 2023 /PRNewswire/ — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one- stop financial supermarket in Hong Kong, today announced that its Board of Directors approved a share repurchase program with authorization to purchase up to 1,000,000 ordinary shares of AGBA with a maximum of $10,000,000 to be expended. The share repurchase program reflects AGBA’s commitment to returning value to its shareholders, while maintaining the financial flexibility to invest in growth opportunities. The program also reflects the company’s confidence in its future prospects.

Wing-Fai Ng, Group President, AGBA Group Holding Limited said, “Creating and defending shareholder value is a core focus of AGBA. Our scale, combined with the strength of our business and the significant opportunities arising from China’sreopening, enables us to continue investing for the long term, while also opportunistically buying back stock through a repurchase program. This program is a direct reflection of our belief that our shares are significantly undervalued, and a demonstration of our confidence in the business and the long-term opportunity ahead.”

AGBA may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and regulations. Open market repurchases will be made in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended Exchange Act.

The manner, timing and amount of any shares repurchases will be determined by AGBA’s management in its discretion based on its evaluation of various factors, including the trading price of the ordinary shares, market and economic conditions, regulatory requirements and other corporate considerations.

This authorization expires on April 18, 2024, and may be suspended or discontinued at any time and does not obligate the company to acquire any amount of ordinary shares.

AGBA GROUP (NASDAQ: ‘AGBA’) PRESENTS ITS BUSINESS CAPABILITIES IN CAPTURING GROWTH IN THE GREATER BAY AREA OF CHINA

HONG KONG, May 30, 2023 /PRNewswire/ — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, released a comprehensive summary report detailing its business capabilities in capturing growth in the Greater Bay Area of (China) (“GBA”). The report provides an overview of AGBA’s capabilities in the GBA and analyzes how AGBA’s core Health and Wealth offerings stand to benefit from the ongoing integration and development of the GBA.

The GBA is a growing economic powerhouse, consisting of nine cities in Guangdong Province, Hong Kong, and Macau. With a combined population of over 70 million and a GDP of over USD 1.6 trillion, the GBA accounts for more than 12% of China’s GDP. The GBA offers a unique combination of size, economic development, innovation, strategic location, and integrated development.

In this report, we review the Group’s current business capabilities and how that positions AGBA to share and expand its expertise in wealth management, insurance, financial planning and healthcare services in the GBA.

The report also highlights how all of AGBA’s core Health and Wealth industries stand to benefit from Hong Kong’s ongoing integration into the GBA. Access to high quality healthcare services, wealth management and financial planning are becoming increasingly important to individuals and businesses customers in the GBA. AGBA can provide that access.

As an established and experienced operator, AGBA is well-positioned to expand its business and capitalize on the vast GBA growth opportunities that lie ahead. AGBA is confident that it will be able to realize substantial value for its investors as it embarks on further growth in the GBA region.

NEWS

    • AGBA GROUP (NASDAQ: ‘AGBA’) COMMENTS ON ITS SHARE PRICE PERFORMANCE SINCE LISTING IN NOVEMBER 2022NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, today provided context for its share price performance since the de-SPAC transaction in November 2022, which has fallen short of AGBA’s expectations.
    • PR Newswire•2 months agoNASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, released a comprehensive summary report detailing its business capabilities in capturing growth in the Greater Bay Area of (China) (“GBA”). The report provides an overview of AGBA’s capabilities in the GBA and analyzes how AGBA’s core Health and Wealth offerings stand to benefit from the ongoing integration and development of the GBA.
    • PR Newswire•2 months agoNASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, today published its financial results for the first quarter of 2023. The Group reported revenue of USD$11.1m, which is 5 times higher compared to Q1 2022.
    • GlobeNewswire•2 months agoRevenue for Q1 2023 of USD$11.1m, up 533% on the same period in 2022 HONG KONG, May 15, 2023 (GLOBE NEWSWIRE) — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, today published its financial results for the first quarter of 2023. The Group reported revenue of USD$11.1m, which is 5 times higher compared to Q1 2022. During March 2023, the Group recorded the highest level of new business applications in the past three years. AGBA expects
    • GlobeNewswire•2 months ago– New AGBA investor presentation highlights its potential to drive growth through innovation, including via AI and proprietary technology HONG KONG, May 09, 2023 (GLOBE NEWSWIRE) — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, released its WealthTech and HealthTech Innovations presentation to its investors. Providing an in-depth overview of the company’s proprietary technologies, the presentation showcase AGBA’s commitment to innova
    • New York City Police Department Deploys AI Robots to Enhance Law Enforcement
    • PR Newswire•2 months agoNASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, released its WealthTech and HealthTech Innovations presentation to its investors. Providing an in-depth overview of the company’s proprietary technologies, the presentation showcases AGBA’s commitment to innovation and customer excellence.
    • PR Newswire•3 months agoAGBA Group Holding Limited (Nasdaq: “AGBA”), a leading one-stop financial supermarket in Hong Kong makes certain clarifications to their projected revenue, franchise strength, and engagement with investors and analysts.
    • PR Newswire•3 months agoNASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one- stop financial supermarket in Hong Kong, today announced that its Board of Directors approved a share repurchase program with authorization to purchase up to 1,000,000 ordinary shares of AGBA with a maximum of $10,000,000 to be expended. The share repurchase program reflects AGBA’s commitment to returning value to its shareholders, while maintaining the financial flexibility to invest in growth opportunities. The program also r
    • GlobeNewswire•3 months agoA comprehensive investor-focused overview offers key insights into the company’s financials, management team, and investment thesis. The release of these in-depth investor materials underscores AGBA’s ongoing commitment to transparency and its dedication to providing valuable resources to investors. HONG KONG, April 14, 2023 (GLOBE NEWSWIRE) — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), the leading one-stop financial supermarket in Hong Kong, has released an extensive introduction pack
    • PR Newswire•3 months agoNASDAQ-listed AGBA Group Holding Limited “AGBA” today announced that it has entered into a sale and purchase agreement, dated 5 April 2023, to acquire Sony Life Financial Advisers Pte Ltd, a duly licensed financial adviser and insurance broker in Singapore. AGBA, together with its subsidiary, the “AGBA Group”, is a leading one-stop financial supermarket headquartered in Hong Kong.

MANAGEMENT TEAM

MR. WING FAI NG

Chairman and Executive Director

Mr. Wing Fai NG is the Chairman and Executive Director of AGBA Group Holding Limited (AGBA).

Mr. Ng earned his reputation in restructuring and transforming financial institutions in Asia in investment banking and private equity. He was the Managing Partner and Founding Partner of Primus Pacific Partners; an Asian private equity fund focused on financial services. At Primus Pacific Partners, he oversees substantial investments in New China Life Insurance Co., Ltd., the fourth largest life insurance company in China, EON Bank, the seventh largest bank in Malaysia, and many significant proprietary investments worldwide with a value of over USD2 billion.

Mr. Ng joined Fubon Financial Holding Co., Ltd. (“Fubon Financial”), the largest financial service conglomerate in Taiwan, in 2000 as the Group Managing Director reported to the board and the founding Tsai Family. He was in charge of Fubon Financial’s overall strategy, capital markets, merger, and acquisition activities. In addition, he initiated a group-wide reorganization, driving the consumer banking business, customer relationship management system, and financing programs.

Among his many regional transactions, Mr. Ng represented and advised the Tsai family and Fubon Financial in its USD850 million strategic alliance with Citigroup in 2000. He also orchestrated the International Bank of Asia acquisition in Hong Kong in 2004. In addition, he led the winning bids to acquire Taipei Bank in Taiwan for USD2.3 billion the following year. Before his position at Fubon Financial, Mr Ng served as the Managing Director and Head of the Asia-Pacific Financial Institutions Group at Salomon Smith Barney (now known as Citigroup).

Mr. Ng received his undergraduate degree from the University of Cambridge where was a Jardine Scholar, and had an MBA from Harvard.

MS. ALMOND WONG

Executive Director

Ms. Almond WONG is the Executive Director and Group Chief Operating Officer of AGBA Group Holding Limited (AGBA).

Ms. Wong is also the Acting Chief Executive Officer of OnePlatform.  OnePlatform is one of the key pillars of AGBA, a comprehensive Finbiz-as-a-Service (FaaS) platform that expands the opportunity to financial advisors, brokers, agents, and financial institutions.

Ms. Wong has a wealth of experience in both people and operations management.  In addition, she brings unparalleled expertise across business transformation, organizational development, corporate cultural building, talent engagement and development, and internal communication.

Ms .Wong is driving OnePlatform to become a unique, omnichannel one-stop financial business service platform in the Greater Bay Area.  In addition, she works closely with the management team to optimize operational efficiency across the Group.

Before joining AGBA, Ms. Wong worked for a number of renowned multinational corporations, including AXA, SunLife Financial, Hutchison Ports, CSL, and Wyeth.

Ms. Wong earned her Master of Business Administration from the University of Leicester and she completed the Advanced Management Program at Harvard Business School.

MR. FELIX WONG

Independent Director

Mr. Felix Yun Pun WONG currently acts as the Chief Financial Officer of Inception Growth Acquisition Limited, a publicly listed special purpose acquisition corporation (NASDAQ: IGTA). He has acted in this capacity since April 9, 2021. He has years of executive experience with multiple leadership positions and a track record in helping private companies enter the public market. He has been the principal of Ascent Partners Advisory Service Limited, a finance advisory firm, since March 2020. From November 2017 to December 2020, Mr. Wong held the position of Chief Financial Officer at Tottenham Acquisition I Limited, a publicly listed special purpose acquisition corporation, which merged with Clene Nanomedicine Inc. (NASDAQ: CLNN) in December 2020. From August 2015 to September 2017, he served as Chief Financial Officer at Raytron Technologies Limited, a leading Chinese national high- tech enterprise. His main responsibilities in these rules have included overseeing the financial functions of the firms, assisting in establishing corporate ventures for investment, and working on deal origination of new businesses in the corporate groups. Prior to these efforts, he was Chief Financial Officer and Executive Director of Tsing Capital from January 2012 to July 2015, where he managed four funds with a total investment amount of US$600 million and focused on environmental and clean technology investments. Mr. Wong also served as senior director and chief financial officer of Spring Capital, a US$250 million fund, from October 2008 until June 2011. Additionally, Mr. Wong was the chief financial officer of Natixis Private Equity Asia from November 2006 till October 2008 and an associate director of JAFCO Asia from March 2002 to October 2006. Mr. Wong was a finance manager for Icon Medialab from July 2000 to December 2001, a senior finance manager of Nielsen from August 1998 to July 2000, Planning-Free Shopper from April 1992 to August 1998, and an auditor at PricewaterhouseCoopers from August 1989 until March 2000. Mr. Wong earned his Masters of Business degree in 2003 from Curtin University in Australia and a Professional Diploma in Company Secretaryship and Administration from the Hong Kong Polytechnic University in 1989.

MR. BRIAN CHAN

Independent Director

Mr. Brian CHAN has over 23 years of experience handling litigations for civil claims, intellectual property rights protection and enforcement. Since September 2007 to present, Mr. Chan has been a Senior Partner at Chan, Tang & Kwok Solicitors, a member of the International Trademark Attorneys Association. From September 1995 to August 2007 he was an Associate at Baker & McKenzie, Associate at Stephenson Harwood & Lo, Partner at Stevenson, Wong & Co., Solicitors and Consultant at Benny Kong & Peter Tang. Additionally, Mr. Chan has acted as a Counsel to various Hong Kong and cross-border mergers and acquisitions and commercial matters since August 1999. Mr. Chan is also a frequent speaker on legal issues for intellectual property rights for the Hong Kong Productivity council. Mr. Chan graduated with a Bachelor of Laws Degree and passed the Solicitors’ Finals of the Law Society of England and Wales in 1993.

MR. THOMAS NG

Independent Director

Mr. Thomas NG has 30 years of broad experience engaging in the fields of Education, Media, Retailing Marketing and Finance. He is a pioneer of IT in education and he was the author of “Digital English Lab,” one of the first series of digital books in Hong Kong. Since September 2018, he has been the Chief Executive Officer of e-chat, an IPFS block chain social media focused company. From March 2017 to April 2018, Mr. Ng was the Chief Financial Officer of Duofu Holdings Group Co. Limited. In February 2016, Mr. Ng founded Shang Finance Limited and was the Chief Executive Officer until February 2017. From March 2015 to November 2015, Mr. Ng was the Chief Financial Officer of World Unionpay Group Shares Limited. In August 2003, Mr. Ng established Fuji (Hong Kong) Co. Ltd. and was the Chief Executive Officer until December 2014. Mr. Ng obtained a Certificate of Education majoring in English from the University of Hong Kong in 2000.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHTEEN THOUSAND USD BY A THIRD PARTY, EDM MEDIA LLC FOR A ONE DAY AGBA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: GNPX) Profile

OUR NEW PROFILE IS:   (NASDAQ: GNPX)

________________________

GNPX HAS ALREADY RECEIVED FAST TRACK DESIGNATION FOR ACCLAIM 2

GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO ADVANCE TO PHASE 2 EXPANSION PORTION OF ACCLAIM-1 CLINICAL TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER 

INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

CHECK OUT THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

We have another profile for you to research for Tomorrow’s session.

This is a company you are definitely going to want to research immediately.

Pull up GNPX right away.

This one ran over 5% when we looked at it last time.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Rodney Varner, CEO of Austin-based biotech company Genprex, stands at the podium during the closing bell ceremony for the Nasdaq exchange in 2018 following the company's initial public offering of stock. [Photo courtesy Genprex]

Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans.

ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body.

The Company’s lead product candidate, REQORSA™ is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer.

Genprex’s diabetes gene therapy approach consists of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas.

In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.

Research And Development Pipeline

GNPX Email Image 1.0

CATALYSTS

– Addressing unmet medical need in large markets through the buildout of a robust pipeline of new drug candidates and drug combinations.

– Leveraging a gene therapy platform; Genprex’s non-viral ONCOPREX® Nanoparticle Delivery System is designed to deliver a variety of therapeutic genes to fight multiple types of cancer.

– REQORSATM immunogene therapy, the first systemically delivered gene therapy used for cancer in humans, can be combined with top-selling cancer drugs and may improve their benefits.

– Genprex has demonstrated clinical achievement with REQORSA in two clinical trials, showing a favorable safety profile and evidence of efficacy in lung cancer.

– GPX-002, Genprex’s diabetes gene therapy, works to transform alpha cells in the pancreas into insulin producing beta-like cells. A Phase 1 clinical trial could be the first-ever gene therapy tested in humans for diabetes.

– Advancing novel gene therapies in diseases with large markets and unmet needs.

– Two NSCLC trials currently enrolling; both with FDA Fast Track Designations.

– World class academic partners.

GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO ADVANCE TO PHASE 2 EXPANSION PORTION OF ACCLAIM-1 CLINICAL TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER 

CLINICAL TRIALS

ONC-001

EVALUATING THE SAFETY OF REQORSA® IMMUNOGENE THERAPY AS A MONOTHERAPY (COMPLETED)

A Phase 1 dose escalation trial was conducted at The University of Texas MD Anderson Cancer Center evaluating the systemic, intravenous delivery of REQORSA® (TUSC2/FUS1) as a monotherapy in stage IV recurrent, metastatic lung cancer patients. The primary objective of this Phase 1 trial was to assess the toxicity of REQORSA administered systemically and intravenously, to determine the maximum tolerated dose, or MTD, and to determine a recommended Phase 2 dose of REQORSA alone.

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

The study showed for the first time that a tumor suppressor gene can be delivered systemically, intravenously and selectively to a patient’s cancer cells using a systemic nanoparticle vector. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients. REQORSA was well tolerated with tumor responses noted in lung primary and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous REQORSA selectively and preferentially targeted patients’ cancer cells.

Metabolic Tumor Response in a Metastatic Lung Cancer Subject

This subject survived after subsequent therapy more than seven years after the final treatment with REQORSA, to our knowledge, without evidence of cancer progression in the responding sites.

ONC-002

COMBINING REQORSA® IMMUNOGENE THERAPY WITH TARCEVA (ERLOTINIB)

PHASE 1 PORTION COMPLETED; PHASE 2 PORTION NO LONGER ENROLLING DUE TO OUR CHANGE OF FOCUS TO CONDUCT ACCLAIM-1

A Phase 1/2 clinical trial evaluated REQORSA® in combination with Tarceva® in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on Tarceva therapy.  Patients without the EGFR mutation represent the vast majority of lung cancer patients. However, such patients generally are not candidates for Tarceva therapy.


In the Phase 2 trial combining REQORSA with Tarceva, subjects received REQORSA in combination with Tarceva every 21 days until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred first. We believe that the results from the Phase 2 trial are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is three months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of Gilotrif (afatinib) in a comparable group of patients.

REQORSA + Tarceva Combination: Phase 2 data in subjects with or without EGFR mutations
ACCLAIM-1
COMBINING REQORSA™ IMMUNOGENE THERAPY WITH TAGRISSO (OSIMERTINIB)Preliminary analysis of the interim data from the Phase 2 portion of our ONC-002 trial supported our belief that REQORSA™ may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the U.S. Food and Drug Administration, or FDA. Data from our clinical trials, along with our preclinical data, provided the basis for our application for a Fast Track Designation, which was granted by FDA on January 14, 2020.In granting our Fast Track Designation, the FDA found that REQORSA may provide a benefit over existing therapies for patients whose tumors progress on AstraZeneca’s Tagrisso. The FDA Fast Track Designation is for use of REQORSA in combination with TKI Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with Tagrisso. We believe that the Fast Track Designation provides a clearly defined pathway toward FDA approval of the combination of REQORSA with Tagrisso.We initiated the Acclaim-1 clinical trial in June 2021, a Phase 1/2 clinical trial of REQORSA combined with Tagrisso. To learn more about Acclaim-1, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.
ACCLAIM-2
COMBINING REQORSA™ IMMUNOGENE THERAPY WITH KEYTRUDA (PEMBROLIZUMAB)Researchers at MD Anderson Cancer Center have conducted preclinical studies evaluating REQORSA™ in combination with anti-PD1 checkpoint inhibitors, including Merck’s Keytruda.Positive and encouraging data indicate that REQORSA is synergistic with immunotherapies.In April 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2 with pembrolizumab, demonstrating that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells, that had metastatic lung cancer.In November 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2, pembrolizumab and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the combination of TUSC2 increases the effectiveness of pembrolizumab and chemotherapy, and thus, may improve on first-line standard of care for lung cancer.In May 2020, we entered into a worldwide, exclusive license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson for the use of TUSC2 in combination with immunotherapies, including Keytruda, and also for the use of TUSC2 in a three-drug combination of TUSC2, immunotherapy and chemotherapy.In December 2021, we received Fast Track Designation from the FDA for use of REQORSA in combination with the checkpoint inhibitor Keytruda for the treatment of advanced NSCLC patients whose tumors progressed after treatment with Keytruda.In March 2022, we opened the Acclaim-2 clinical trial for patient enrollment, a Phase 1/2 clinical trial of REQORSA combined with Keytruda. To learn more about Acclaim-2, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.
DIA-001STUDYING GPX-002 IN DIABETIC MICE
Researchers at the University of Pittsburgh have conducted preclinical studies evaluating GPX-002 in diabetic mice models. In vivo mice studies have found that GPX-002 restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.These researchers are continuing to conduct preclinical studies in diabetic primates. Once sufficient preclinical data has been generated, we expect to begin a Phase 1 clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Pdx1/MafA Bibliography page.
ONCOLOGY COMBINATION TREATMENT APPROACH
Our oncology program uses a modern combinational treatment approach to fight cancer, utilizing our lead drug candidate, REQORSA™ immunogene therapy and our unique, proprietary, non-viral ONCOPREX® nanoparticle delivery system combined with approved targeted therapies and immunotherapies. This enables us to offer hope to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them.ONCOLOGY COMBINATION TREATMENT APPROACHOur research indicates that when REQORSA, our lead drug candidate for non-small cell lung cancer (NSCLC), is combined with targeted therapies such as Tarceva (erlotinib) or Tagrisso (osimertinib) or with immunotherapies such as Opdivo (nivolumab) or Keytruda (pembrolizumab), REQORSA is synergistic with those drugs, meaning that the combination is more effective than either drug alone. We believe that by combining REQORSA with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer drugs into the large majority of patients who do not now benefit from them, either because the patients’ tumors do not have the molecular profiles that indicate effectiveness of those drugs, or because the patients have developed resistance to those drugs after receiving them for some period of time.To learn more about our combination trials utilizing our oncology combination treatment approach, refer to our Pipeline and Clinical Trials pages.
TARGETED THERAPIES
Targeted therapies work by targeting the cancer or disease’s specific gene, protein or tissue that contributes to the disease while sparing normal tissue. Unfortunately, targeted therapies require patients to have an activating genetic mutation specific to the drug. In NSCLC, the vast majority of lung cancer patients do not have the genetic mutations that qualify them for targeted therapies, such as the EGFR or ALK gene. In addition, the few patients who do have the genetic mutation qualifying them to receive targeted therapies are likely to develop resistance to these drugs over time.In January 2020, we received a United States FDA Fast Track Designation for use of REQORSA in combination with EGFR inhibitor Tagrisso for the treatment of NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. The median length of time that patients are treated with Tagrisso before their tumors progress is approximately eighteen (18) months.
IMMUNOTHERAPIES
Immunotherapy is a type of treatment that helps the immune system fight disease. Biomarker testing can help determine if high levels of PD-1/PD-L1 proteins are detected in the patient, signifying that the body’s immune system is not working to fight cancer or disease as it should. These patients could qualify for approved immunotherapies, however, not all patients benefit from immunotherapies.Genprex is conducting preclinical studies to evaluate REQORSA in combination with checkpoint inhibitors. Preclinical data indicate that Genprex’s lead drug candidate is synergistic with checkpoint inhibitors, such as Merck’s Keytruda, meaning that the combination of drugs may be more effective than checkpoint inhibitors alone. Preclinical data also indicates that a three-drug combination of a checkpoint inhibitor, chemotherapy, and REQORSA may be more effective than the two-drug combination of a checkpoint inhibitor and chemotherapy.
MARKET OPPORTUNITY
AstraZeneca’s Tagrisso had more than $4 billion in worldwide gross sales in 2020, and Tagrisso is AstraZeneca’s highest grossing product. Given Genprex’s Fast Track Designation and Tagrisso’s status as the current standard of care in EGFR-mutated NSCLC, we have prioritized the clinical development of REQORSA in combination with Tagrisso. We believe this regulatory pathway positions us well in the $17.9 billion global lung cancer market, especially given the advantages of our Fast Track Designation status.Merck’s Keytruda generated more than $14 billion in worldwide sales in 2020, and Keytruda is Merck’s highest grossing product. Keytruda is the standard of care in non-EGFR mutated NSCLC. Genprex plans to initiate a Phase I/II clinical trial evaluating REQORSA in combination with pembrolizumab.

PROGRAMS
LUNG CANCER

Cancer is a complex disease that can start in any site in the body when a tissue grows out of control and inhibits the body’s normal functioning. At the cell level, cancer often involves the dysregulation of multiple genes and cellular pathways, leading to the cell’s inability to maintain proper cellular functions. Re-establishing or blocking these pathways can be done through many therapeutic approaches, including gene therapy. More general information about cancer can be found at The American Cancer Society.
LUNG CANCER
Genprex’s oncology program is focused on developing new treatments for cancer. Our initial therapeutic target is lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).According to the World Health Organization in 2020, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver, or stomach cancers. In 2020, there were more than 2 million new lung cancer cases and 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2022 there will be more than 236,000 new cases of lung cancer and more than 130,000 deaths from this disease. NSCLC represents 84% of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. SCLC represents about 13% of lung cancer patients and the five-year survival rate for patients with SCLC with distant spread is 3 percent. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC and SCLC in the United States and globally, and we believe REQORSA may be suitable for the majority of lung cancer patients.
DIABETES
Our diabetes gene therapy candidate, GPX-002, is being developed for the treatment of diabetes.According to the U.S. Center for Disease Control, 37 million Americans, or approximately 11% of the population, have diabetes. It is also believed that more than 96 million Americans have prediabetes, which represents approximately 38% of the U.S. population. The prevalence of this chronic disease is continuing to rise.Chronic diabetes conditions include Type 1 diabetes and Type 2 diabetes, both of which lead to excess sugar in the blood and can cause serious health problems. Left untreated, high blood sugar levels can damage eyes, kidneys, nerves, and the heart, and can also lead to coma and death.

TECHNOLOGY

REQORSA® IMMUNOGENE THERAPY

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

Our lead product candidate, REQORSA®  immunogene therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda.

The active ingredient in our lead product candidate, REQORSA, is the TUSC2 gene, a tumor suppressor gene.

REQORSA consists of the TUSC2 gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance.

We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy used for cancer in humans.

OVERCOMING DRUG RESISTANCE

REQORSA is a pan-kinase inhibitor shown to simultaneously inhibit the EGFR and AKT oncogenic kinase pathways in vitro and in vivo. Once the cancer cell takes up the nanoparticle containing TUSC2, it is reprogrammed to die. Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that REQORSA’s multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops.

To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our Clinical Trials and TUSC2 Bibliographypages.

GPX-002

DIABETES GENE THERAPY

GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

Image source: Osipovich, Anna & Magnuson, Mark. (2018). Alpha to Beta Cell Reprogramming: Stepping toward a New Treatment for Diabetes. Cell Stem Cell. 22. 12-13. 10.1016/j.stem.2017.12.012.

Diabetic mice studies show that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.

The diabetes gene therapy was developed by Dr. George Gittes, a researcher at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, where preclinical research is ongoing. GPX-002 has been tested in vivo in mice and nonhuman primates. Once sufficient preclinical data has been generated, we expect to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.

To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Clinical Trials and Pdx1/MafA Bibliography pages.

ONCOPREX® NANOPARTICLE DELIVERY SYSTEM

THE FIRST SYSTEMIC GENE THERAPY DELIVERY PLATFORM USED IN HUMANS FOR CANCER

Our oncology drug development program utilizes our unique, proprietary non-viral ONCOPREX Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with our initial product candidate, REQORSA® immunogene therapy.

DESIGNED TO DELIVER CANCER-FIGHTING GENES SYSTEMICALLY

The ONCOPREX platform has been designed and optimized to deliver cancer-fighting genes into the patient’s body systemically. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. Our nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and have been clinically shown to deliver molecular kinase inhibitors effectively.

OPTIMIZED PARTICLE SIZE

Our systemic, nanoparticle, non-viral delivery system, which is being used in our clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to be small enough to cross tight barriers in the lungs but large enough to avoid accumulation in the liver, spleen and kidney. The nanoparticles have been shown to be taken up by tumor cells after REQORSA administration at up to 33 times the rate they are taken up by normal cells. The cationic charge of the lipid nanoparticles targets cancer cells, which facilitates endocytosis. Once inside the cancer cell, the TUSC2 gene activates signaling pathways that result in cell destruction or apoptosis.

ENHANCED SAFETY AND EFFICACY DESIGN

We have administered REQORSA to more than 50 patients in Phase 1 and 2 clinical trials using our systemic, proprietary, non-viral delivery system.

A Phase 1 clinical trial showed that systemic, intravenous therapy using the ONCOPREX Nanoparticle Delivery System was shown to selectively and preferentially target primary and metastatic tumor cells, resulting in clinically significant anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.

Our earlier clinical trials have also shown that the ONCOPREX Nanoparticle Delivery System is well tolerated in humans and can safely deliver high therapeutic doses. We believe the ONC-001 clinical trial was the first systemic gene therapy clinical trial using a nanoparticle delivery system to deliver a tumor suppressor gene.

GENPREX (NASDAQ:GNPX) RELEASES NEW PATIENT VIDEO INTERVIEW DESCRIBING POSITIVE EXPERIENCE IN CLINICAL

AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is working with world-class institutions in developing new drugs from the company’s pipeline of gene therapy candidates in order to provide novel treatment approaches. Its oncology program utilizes its proprietary non-viral ONCOPREX® Nanoparticle Delivery System, which Genprex believes is the first systemic gene therapy delivery platform used for cancer in humans. The company’s lead drug candidate is called REQORSA®. The immunogene therapy (also known as quaratusugene ozeplasmid) is for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System. The drug may be helpful for treating patients who have already demonstrated drug resistance to other treatments.

Genprex, Friday, June 2, 2023, Press release picture

On the heels of the release of recent positive safety and early efficacy data related to the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial for non-small cell lung cancer evaluating REQORSA in combination with Tagrisso, Genprex has released a new patient video featuring an NSCLC patient from the phase 1 portion of its Acclaim-1.

All patients in the trial had disease progression on their previous cancer treatment. In the video, an NSCLC patient who experienced extended Progression Free Survival (PFS) in the trial describes her positive experience taking REQORSA – Genprex’s lead drug candidate which she is still taking – while participating in the phase 1 portion of the Acclaim-1 clinical trial.

“While on REQORSA treatment, my doctor noted that the lung cancer lesions have not grown and there is no new growth,” said the NSCLC patient in the Phase 1 portion of Acclaim-1. “I believe the REQORSA treatment has benefited my life and has increased my time.”

The patient’s positive experience is encouraging – she was able to continue working full-time while participating in the clinical trial. She experienced only minor side effects from REQORSA and so far has experienced more than 10 months of progression-free survival.

NSCLC is the most common type of lung cancer, accounting for about 82% of all cases. While there have been some advances in treatment options for NSCLC, such as chemotherapy, radiation therapy and targeted therapies, the overall survival rate for patients with advanced NSCLC remains low. The five-year survival rate for patients with distant spread is 7%.

Genprex has disclosed favorable preliminary clinical data from the Acclaim-1 clinical trial’s phase 1 dose-escalation segment in an abstract published at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings show that REQORSA was well tolerated with no dose-limiting toxicities. Furthermore, Genprex reported preliminary evidence of efficacy in the phase 1 portion of the study.

“We are thrilled to have our abstract, which reports positive results from the phase 1 portion of our Acclaim-1 clinical trial, published at the ASCO Annual Meeting,” said Mark Berger, MD, Chief Medical Officer at Genprex. “We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed. In fact, the Safety Review Committee has just approved our advancement into the phase 2 expansion portion of the clinical trial.”

As noted above, the company also announced that its Safety Review Committee (SRC) has approved the advancement of the Acclaim-1 clinical trial to the phase 2 expansion portion of the trial. The SRC has examined the full safety data and has approved the recommended phase 2 dose of REQORSA, which is 0.12 mg/kg, twice the highest dose level delivered in Genprex’s previous clinical trials. This approval is a significant milestone in REQORSA’s development program. The SRC’s recommendation to advance the trial to the phase 2 expansion portion is a significant milestone for REQORSA.

Genprex’s REQORSA drug seems to be a promising innovation in cancer treatment. REQORSA’s unique approach of targeting the tumor suppressor gene TUSC2 sets it apart from other cancer treatments and other genetic medicines. Similar to companies like Bluebird Bio or Editas Medicine Inc., who are developing innovative therapies for rare diseases or using different gene editing techniques for cancer, Genprex’s REQORSA has the potential to be a game-changer in the field of cancer treatment through gene therapy.

INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

APRIL 18, 2023

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Study adds to the growing body of research examining TUSC2 as a target for multiple other cancers

TUSC2 is the tumor suppressor gene used in the Company’s lead drug candidate, REQORSA® (quaratusugene ozeplasmid)

AUSTIN, Texas — (April 18, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that it functions as a novel tumor suppressor for glioblastoma. TUSC2 is the tumor suppressor gene that is reexpressed in tumors using REQORSA® Therapy treatment, Genprex’s lead drug candidate. Genprex has no affiliation with these researchers.

The independent researchers presented their abstract, titled, “Investigating TUSC2 for its tumor suppressive functions in glioblastoma and its role in gliomagenesis,” at the 2023 American Association for Cancer Research Annual Meeting on April 17. The abstract reports TUSC2 protein expression, but not mRNA expression, to be significantly decreased in glioblastoma as compared to normal brain. TUSC2 protein is destabilized in glioblastoma due to polyubiquitination by E3 ligase, neural precursor cell-expressed developmentally downregulated gene 4 (NEDD4), and degradation by the proteasome. The researchers determined that NEDD4 targets TUSC2 on lysine residue K71.

The researchers also reported that TUSC2 overexpression reduced colony formation and neurosphere formation and promoted apoptosis of glioblastoma cells in vitro, and suppressed tumor growth in vivo. Further, glioblastoma cells with CRISPR-mediated knockout (KO) of TUSC2 were highly aggressive in vitro and in vivo, demonstrating the role of TUSC2 as a novel tumor suppressor for glioblastoma.

In the study, researchers performed immunoprecipitation-mass spectrometry analysis to identify TUSC2-interacting proteins in both normal human astrocytes and glioblastoma cell lines. Results showed 95 and 88 TUSC2-interacting proteins in astrocytes and glioblastoma cell lines respectively, and 27 proteins were found to interact with TUSC2 in both astrocytes and glioblastoma.

“This research supports the growing body of studies evaluating TUSC2 as a target in oncology, and potentially an effective treatment, for many types of cancer,” said Rodney Varner, Chairman, President and Chief Executive Officer of Genprex. “We are encouraged by the increasing number of research institutions and independent researchers producing positive data on TUSC2, which provide additional support for REQORSA® and its therapeutic potential against cancers.”

REQORSA® Therapy is currently in development for the treatment of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). REQORSA® consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (the Company’s ONCOPREX® Nanoparticle Delivery System) with a positive electrical charge. REQORSA® is injected intravenously and specifically targets cancer cells, taking advantage of leaky tumor vascularity, increased tumor pinocytosis, and attraction of positively charged lipid nanoparticles to negatively charged cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue.

According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers. More than 13,000 Americans were expected to receive a glioblastoma diagnosis in 2022. Glioblastoma accounts for 49.1 percent of all primary malignant brain tumors. There have only been five drugs and one device ever approved by the U.S. Food and Drug Adminstration for the treatment of glioblastoma.

Other independent researchers and studies have found that TUSC2 therapy may benefit other types of cancer, including head and neck, breast (including triple-negative breast cancer), renal cell (kidney), thyroid, and soft tissue sarcoma, as well as NSCLC and SCLC. For more information and additional studies supporting TUSC2, please refer to our Bibliography Page.

NEWS

BELL2BELL PODCAST FEATURING CEO RODNEY VARNER & CFO RYAN CONFER OF GENPREX, INC. (NASDAQ: GNPX)

JULY 6, 2023

Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. In this interview, Varner and Confer discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline.

Read More


GENPREX GRANTED CHINESE PATENT FOR REQORSA® IMMUNOGENE THERAPY IN COMBINATION WITH PD-1 ANTIBODIES TO TREAT CANCERS

JULY 5, 2023

Provides Additional Protection in Large Markets for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Read More


GENPREX RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR REQORSA® IMMUNOGENE THERAPY IN COMBINATION WITH TECENTRIQ® FOR THE TREATMENT OF SMALL CELL LUNG CANCER

JUNE 28, 2023

Third FDA Fast Track Designation Further Validates the Potential of REQORSA

AUSTIN, Texas — (June 28, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S.

Read More


GENPREX’S ASCO COMPANY UPDATE: DR. MARK BERGER, CHIEF MEDICAL OFFICER, SHARES INSIGHTS ON BELL2BELL PODCAST

JUNE 8, 2023

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

Read More


GENPREX (NASDAQ: GNPX) RELEASES NEW PATIENT VIDEO INTERVIEW DESCRIBING POSITIVE EXPERIENCE IN CLINICAL TRIAL

JUNE 1, 2023

On the heels of the release of recent positive safety and early efficacy data related to the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial for non-small cell lung cancer evaluating REQORSA in combination with Tagrisso, Genprex has released a new patient video featuring an NSCLC patient from the phase 1 portion of its Acclaim-1.

Read More

GENPREX PUBLISHES POSITIVE CLINICAL DATA FROM PHASE 1 PORTION OF ACCLAIM-1 CLINICAL TRIAL EVALUATING REQORSA® IMMUNOGENE THERAPY IN NON-SMALL CELL LUNG CANCER AT THE 2023 ASCO ANNUAL MEETING

MAY 25, 2023

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed

Read More


GENPREX UNVEILS NEW VIDEO FEATURING CHIEF MEDICAL OFFICER DISCUSSING POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM

MAY 23, 2023

Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at the 2023 American Association of Cancer Research (AACR) annual meeting

Read More


GENPREX TO PARTICIPATE AND PRESENT AT UPCOMING MAY INDUSTRY AND INVESTOR CONFERENCES 

MAY 8, 2023

Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

APRIL 19, 2023

Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene

Read More


INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

APRIL 18, 2023

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Read More


GENPREX CEO COMMENDS FDA’S INITIATIVE TO ACCELERATE APPROVAL PROCESS FOR GENE THERAPIES

MARCH 23, 2023

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options

Read More


GENPREX TO PRESENT AT BIOPROCESSING SUMMIT CONFERENCE

MARCH 13, 2023

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies

Read More


GENPREX TO PARTICIPATE IN MARCH INVESTOR AND INDUSTRY CONFERENCES 

MARCH 8, 2023

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes

Read More


GENPREX, INC. ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING WITH A SINGLE, HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR

FEBRUARY 27, 2023

The gross proceeds from the offering are expected to be approximately $4 million, before deducting placement agent fees and other estimated offering expenses.

Read More


GENPREX ANNOUNCES GROUNDBREAKING DATA FROM NON-HUMAN PRIMATE STUDY EVALUATING NOVEL GENE THERAPY TO TREAT TYPE 1 DIABETES AT 16TH ANNUAL INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENT FOR DIABETES 2023

FEBRUARY 23, 2023

Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline

Read More


GENPREX SIGNS EXCLUSIVE LICENSE TO ADDITIONAL DIABETES TECHNOLOGY WITH THE UNIVERSITY OF PITTSBURGH

JANUARY 5, 2023

Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes

Read More


GENPREX ANNOUNCES SELECTION OF PRECLINICAL DATA FOR ORAL PRESENTATION AT 16TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES 

JANUARY 4, 2023

Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex’s Gene Therapy Program in Diabetes to be Showcased

Read More

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

DECEMBER 15, 2022

Technology for modulating autoimmunity expands intellectual property portfolio

Read More


GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO PROCEED TO FINAL COHORT IN ACCLAIM-1 PHASE 1 DOSE ESCALATION TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER

DECEMBER 14, 2022

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

Read More


MANAGEMENT

Check out the management team here: https://www.genprex.com/about/company-management/

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY GNPX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(AMEX: TOON) Profile

OUR NEW PROFILE IS:   (AMEX: TOON)

ANALYST SETS $10.00 TARGET AFTER TOON ANNOUNCES A 885% INCREASE IN REVENUE

KARTOON STUDIOS’ PREMIERE OF SHAQ’S GARAGE, STARRING SHAQUILLE O’NEAL, OUTPERFORMS DURING JUNE EXCLUSIVE ON PLUTO TV

LEGIBLE TO PARTNER WITH KARTOON STUDIOS ON DEVELOPMENT AND PUBLICATION OF NEVER-BEFORE-RELEASED STORIES AND CHARACTERS CREATED BY STAN LEE

Hello Everyone,

We have another company for you to put on your radar and research immediately for tomorrow’s session.

This is a company that has closed green 4 sessions in a row as interest is picking up.

With a massive spike in revs, this company is starting to hit a lot of peoples radars.

Pull up TOON immediately.

Let’s take a look at a few of the major catalysts:

POSITIVE ANALYST OUTLOOK:

James McIlree, an analyst at Dawson James Securities, has set a target of $10.00 for Kartoon Studios, Inc. (AMEX: TOON) reflecting his positive outlook on the company’s growth potential. This target suggests 415% in upside potential from (TOON)’s opening price of $1.94 on 7/11/2023. (2)(3)

STRONG REVENUE GROWTH:

Kartoon Studios, Inc. (AMEX: TOON)has experienced significant revenue growth, with a notable 885% increase in Q1 2023 compared to the previous year. This trend indicates the company’s potential to generate substantial returns. (1)

IMPRESSIVE ACQUISITIONS:

The strategic acquisitions made by Kartoon Studios, Inc. (AMEX: TOON), including WOW Unlimited and Ameba TV, have expanded their content creation capabilities and global distribution reach. These acquisitions position the company for further growth and market penetration. (2)(6)(7)

VALUABLE PARTNERSHIPS:

Kartoon Studios, Inc. (AMEX: TOON)has formed valuable partnerships with renowned brands such as TOHO Studios of Japan, allowing them to tap into a broader audience base and explore new markets.(4) On 6/2/2023, (TOON) announced it has partnered for the first time with Powerkids Entertainment to launch a new co-branded kid’s channel, Powerkids Kartoon Channel!, available via various distribution platforms across India and South Asia. (5)

INTELLECTUAL PROPERTY:

Kartoon Studios, Inc. (AMEX: TOON)’sIP portfolio of family-friendly content features the Stan Lee brand, Stan Lee’s Superhero Kindergarten, starring Arnold Schwarzenegger, on Kartoon Channel!; Shaq’s Garage, starring Shaquille O’Neal, coming to Kartoon Channel!; Rainbow Rangers on Kartoon Channel! and Netflix;, Llama Llama, starring Jennifer Garner, on Netflix, and more. (6)

BROADENED GLOBAL REACH:

Kartoon Studios, Inc. (AMEX: TOON) has significantly expanded its global distribution network through the consolidation of its consumer platforms under Genius Networks. This strategic move has bolstered the company’s distribution channels, enabling it to extend its reach to viewers across multiple platforms and regions. Key to this enhanced distribution network is the ownership of Kartoon Channel!, a highly acclaimed family entertainment destination. (7)

EXPANSION INTO CONSUMER PRODUCTS:

Kartoon Studios, Inc. (AMEX: TOON) is making a strategic move into the world of consumer products, exemplified by the recent launch of its Bee and PuppyCat merchandise. This expansion not only opens up an additional revenue stream for the company but also reinforces the brand’s visibility and resonance among its intended audience. The introduction of consumer products allows Genius Brands International, Inc. (AMEX: TOON) to extend its reach beyond the screen and connect with fans on a more tangible level. (8)

DAWSON JAMES ANALYST, JAMES MCILREE, SETS $10.00 TARGET FOR KARTOON STUDIOS, INC. (AMEX: TOON) SIGNALING 415% POTENTIAL UPSIDE (2)(3)

GNUS-1
Source (2)

James McIlree, an analyst at Dawson James Securities, has set a target of $10.00 for Kartoon Studios, Inc. (AMEX: TOON) reflecting his positive outlook on the company’s growth potential. This target suggests 415% in upside potential from (TOON)’s opening price of $1.94 on 7/11/2023. (2)(3)

Source (22)

Listen. Nothing is certain. But looking at Kartoon Studios, Inc. (AMEX: TOON)’s daily chart above and do a little technical analysis using StockCharts.com. You can see the following moving averages as of 7/12/23:(22)

Daily average price is: $2.14 (as of 7/12/23)
50-day moving average: $2.51
100-day moving average: $2.70
200-day moving average: $4.52

Based on the moving average prices, could there be potential for significant growth?

McIlree’s optimistic target of $10.00 is based on his comprehensive research and analysis of Kartoon Studios, Inc. (AMEX: TOON). His positive outlook stems from several key factors, including the company’s impressive revenue growth, as evidenced by the 885% increase in Q1 2023. This strong financial performance highlights Genius Brands’ ability to capitalize on acquisitions and expand its market presence. (2)

Furthermore, McIlree acknowledges the strategic value of Kartoon Studios, Inc. (AMEX: TOON)’s acquisitions, such as WOW Unlimited and Ameba TV, which have strengthened the company’s content creation capabilities and global distribution reach. These acquisitions position Genius Brands favorably to benefit from the growing demand for animated children’s content and explore new markets. (2)

Additionally, McIlree recognizes the company’s valuable partnerships with renowned brands and the strength of its distribution channels, including Kartoon Channel!, YFE, and Ameba TV. These partnerships provide the company with a wide audience reach and multiple avenues for generating revenue. (2)

Those who value McIlree’s analysis and share his optimism about the company’s future prospects may consider further exploration and research regarding potential opportunities associated with Kartoon Studios, Inc. (AMEX: TOON). (2)

Source (1)

On 5/22/2023, Kartoon Studios, Inc. (AMEX: TOON) announced a remarkable 885% increase in revenue for the first quarter of 2023 (Q1 2023), highlighting its strong growth trajectory. The company’s revenue for Q1 2023 reached $14.2 million, a substantial rise from $1.4 million during the same period last year. (1)

To further enhance profitability and streamline operations, Kartoon Studios, Inc. (AMEX: TOON) has embarked on a comprehensive cost-cutting plan. This strategic initiative aims to reduce expenses across various areas, including personnel costs, production spend, lease, and vendor expenses. By implementing these measures, Genius Brands is focused on optimizing efficiency and driving the company towards sustained profitability.

As of March 31, 2023, Kartoon Studios, Inc. (AMEX: TOON) boasts an impressive financial position, with current assets amounting to $114.3 million, working capital of $23.5 million, and total stockholders’ equity of $91.3 million. These strong financial indicators underscore the company’s stability and ability to pursue growth opportunities. (1)

Exciting developments are underway at Kartoon Studios, Inc. (AMEX: TOON), particularly with the highly anticipated premiere of Kartoon Channel!’s, “Shaq’s Garage.” Starring and executive produced by the legendary Shaquille O’Neal, the animated series is set to debut exclusively on Pluto TV, the leading free streaming television service, on June 5th. “Shaq’s Garage” comprises 26 original 11-minute episodes and will be accompanied by a wide range of companion content, influencer collaborations, and a comprehensive social marketing campaign. Genius Brands is also actively developing a robust retail program for “Shaq’s Garage,” expanding the brand’s presence across various consumer product categories.(1)

Source (12)

Unlike many streaming companies experiencing declining subscriptions, Genius Networks, the parent company of Kartoon Channel!, has witnessed a 6% increase in its subscription base since the fourth quarter of 2022. Additionally, subscriber watch time has surged by 15% during the same period. Furthermore, total trial conversions have increased by 13% compared to the previous year.

Kartoon Studios, Inc. (AMEX: TOON)’s success can be attributed to its customer acquisition framework, which leverages data-driven, agile media execution and identifies optimal subscription platforms. The company’s customer acquisition costs have been significantly reduced by over 75% since 2022. These impressive efficiencies in customer acquisition allow Kartoon Studios, Inc. (AMEX: TOON) to allocate fewer resources to marketing and advertising while driving subscriber growth and revenue. (1)

GNUS 5
Source (13)

In line with its commitment to delivering captivating content, Kartoon Studios, Inc. (AMEX: TOON)is set to launch the flagpole STAN LEE and STAN LEE CENTENNIAL, a tribute to the iconic Stan Lee.(1)

The festivities will commence with a documentary on the life of Stan Lee, premiering during the opening weekend of the Tribeca Film Festival on June 10th. Following this, the documentary will be released on Disney+ on June 16th. (1)

Additionally, Kartoon Studios, Inc. (AMEX: TOON) plans to roll out a comprehensive licensing program for Bee and Puppycat, the primary property in its partnership with Toho Studios of Japan, ahead of the Licensing Expo in Las Vegas scheduled for June 13th to 15th. (1)

Kartoon Studios, Inc. (AMEX: TOON)’s strong revenue growth, exciting content offerings, and strategic initiatives position the company for continued success in the children’s entertainment industry. With its robust financial position and a diverse portfolio of engaging properties, Genius Brands is well-positioned to capture the attention of its target audience and drive sustained growth in the future.

KARTOON STUDIOS, INC. (AMEX: TOON) EXPANDS CONTENT CREATION CAPABILITIES WITH STRATEGIC ACQUISITIONS (2)

Source (10)

Kartoon Studios, Inc. (AMEX: TOON) has successfully executed a series of strategic acquisitions that have significantly bolstered its content creation capabilities and expanded its global distribution reach. These acquisitions, which include WOW Unlimited and Ameba TV, have positioned Genius Brands for accelerated growth and enhanced market penetration in the rapidly evolving children’s entertainment industry.(2)(6)(7)

The acquisition of WOW Unlimited Media, a renowned Canadian media company, has brought tremendous value to Genius Brands. Through this partnership, Genius Brands has gained access to WOW Unlimited’s extensive network of content creators, including its subsidiary Frederator Networks. Frederator Networks, known for producing hit animated series such as “Adventure Time” and “The Fairly OddParents,” has a strong track record of creating compelling and highly successful content for children and young adults. This acquisition has further strengthened Genius Brands’ content library and allowed them to tap into the creative expertise of WOW Unlimited’s talented team. (2)(6)(7)

Source (14)

Additionally, the acquisition of Ameba TV has expanded Genius Brands’ global distribution capabilities. Ameba TV, a pioneering children’s streaming service and Amazon Prime Video Channel, has established itself as a trusted platform for high-quality children’s content. By integrating Ameba TV into its portfolio, Genius Brands has gained a wider reach and the ability to distribute its content to a broader audience. (7)

These strategic acquisitions have not only expanded Genius Brands’ content library, but have also provided access to new markets and distribution channels. By harnessing the creative talent and expertise of WOW Unlimited and leveraging the established distribution network of Ameba TV, Genius Brands is well-positioned to deliver its engaging and enriching content to audiences worldwide. (7)

Furthermore, these acquisitions have laid a solid foundation for future growth and market penetration. Genius Brands can now produce a diverse range of high-quality content and distribute it across multiple platforms, including streaming services, television networks, and digital platforms. The increased content creation capabilities and expanded distribution reach enable Genius Brands to capture a larger share of the children’s entertainment market and capitalize on the growing demand for engaging and educational content. (2)(7)

With a robust content library, a strong distribution network, and a clear strategic vision, Genius Brands is poised to continue its upward trajectory in the children’s media industry. The impressive acquisitions made by the company have not only solidified its position as a key player in the market but have also paved the way for future success and innovation. As Genius Brands continues to build on its acquisitions and leverage its expanded capabilities, it is well-equipped to captivate audiences, drive revenue growth, and establish itself as a global leader in children’s entertainment. (2)(6)(7)

KARTOON STUDIOS, INC. (AMEX: TOON) EXPANDS MARKET PRESENCE THROUGH STRATEGIC PARTNERSHIPS (4)(5)

GNUS 8
Source (15)

In a bid to propel its growth and expand its market presence, Kartoon Studios, Inc. (AMEX: TOON)has successfully forged valuable partnerships with renowned brands. These strategic collaborations have positioned the company for further success and provided access to new markets and audiences. (4)(5)

One notable partnership is with TOHO Studios of Japan, a powerhouse in the entertainment industry. By joining forces with TOHO Studios, Genius Brands gains a gateway to tap into the vast Japanese market and leverage the extensive expertise of TOHO Studios in content creation and distribution. This collaboration enables both companies to combine their strengths and resources to create captivating and culturally diverse content that resonates with a broader audience base. The partnership with TOHO Studios presents an exciting opportunity for market expansion, enhanced audience engagement, and creative collaborations.

Additionally, Kartoon Studios, Inc. (AMEX: TOON) announced a groundbreaking partnership with Powerkids Entertainment on June 2, 2023. This milestone collaboration marks the launch of the first-ever co-branded kid’s channel by Genius Brands, known as Powerkids Kartoon Channel!. The channel will be made available through various distribution platforms across India and South Asia, bringing high-quality, family-friendly content to young viewers in the region.

By teaming up with Powerkids Entertainment, a trusted name in the children’s entertainment industry, Genius Brands gains access to local expertise, cultural insights, and an established network. This collaboration allows Genius Brands to deliver engaging and educational content that resonates with the diverse audience in India and South Asia. The partnership with Powerkids Entertainment not only expands Genius Brands’ reach into new markets but also enables the company to connect with a broader audience base and create meaningful connections with young viewers and their families. (4)(5)

The strategic partnerships forged by Kartoon Studios, Inc. (AMEX: TOON) demonstrate the company’s commitment to collaborative efforts that unlock new markets, extend its global footprint, and provide access to a diverse range of content. By joining forces with renowned brands like TOHO Studios and Powerkids Entertainment, Kartoon Studios, Inc. (AMEX: TOON) solidifies its position as a leading player in the children’s entertainment industry. The company is well-positioned for continued growth, innovation, and success as it leverages these valuable partnerships to drive its mission of providing high-quality, captivating content to audiences worldwide.

In addition to its valuable partnerships with renowned brands, Kartoon Studios, Inc. (AMEX: TOON) has also collaborated with basketball legend Shaquille O’Neal, further expanding its market presence and enhancing its brand offerings.(4)(5)

Through the collaboration with Shaquille O’Neal, Kartoon Studios, Inc. (AMEX: TOON)has developed the highly anticipated series “Shaq’s Garage,” which showcases the legendary athlete’s passion for cars and adventure. The show, starring and executive produced by Shaquille O’Neal, is set to premiere on Kartoon Channel! and other distribution platforms, captivating audiences with exciting and entertaining content. (4)(5)

KARTOON STUDIOS, INC. SHOWCASES POWERHOUSE IP PORTFOLIO OF FAMILY-FRIENDLY CONTENT (6)

GNUS 10
Source (16)

STAN LEE, SHAQ, AND JENNIFER GARNER: THE STELLAR LINEUP OF GENIUS BRANDS’ IP OFFERINGS (6)

Kartoon Studios, Inc. (AMEX: TOON) boasts a robust and highly valuable intellectual property (IP) portfolio that encompasses a wide range of family-friendly content. These IP assets play a pivotal role in driving the company’s success and strengthening its position in the children’s entertainment industry. (6)

One of the standout properties in Kartoon Studios, Inc. (AMEX: TOON)’s IP portfolio is the renowned Stan Lee brand. As a true visionary and creator of some of the most iconic superheroes in the Marvel Universe, Stan Lee’s legacy lives on through the compelling content produced by Genius Brands.

Source (16)

One notable production is “Stan Lee’s Superhero Kindergarten,” a vibrant animated series that brings together the imaginative world of superheroes with the star power of Arnold Schwarzenegger. This series, available on Kartoon Channel!, captivates young viewers with its action-packed adventures and valuable life lessons. (6)

Another exciting addition to Genius Brands’ IP lineup is “Shaq’s Garage,” starring the charismatic basketball legend Shaquille O’Neal. This upcoming series on Kartoon Channel! combines Shaq’s passion for cars and thrilling adventures, delivering a unique blend of entertainment and education for young audiences. With Shaquille O’Neal’s star power and larger-than-life personality, “Shaq’s Garage” is set to captivate viewers and establish itself as a beloved brand within Kartoon Studios, Inc. (AMEX: TOON)’s IP portfolio.

“Rainbow Rangers” is another noteworthy property that highlights the diversity and inclusivity of Genius Brands’ content offerings. This animated series, available on both Kartoon Channel! and Netflix, takes young viewers on exciting adventures with a group of courageous girls who protect the environment and its animal inhabitants. With its vibrant animation, engaging storytelling, and strong positive messaging, “Rainbow Rangers” has garnered a loyal fan base and continues to resonate with audiences worldwide.

Additionally, Genius Brands’ IP portfolio includes “Llama Llama,” a heartwarming animated series based on the beloved children’s books by Anna Dewdney. Starring Jennifer Garner as the voice of Mama Llama, this Netflix original production brings the charming and relatable world of Llama Llama to life, captivating young viewers with its endearing characters and valuable life lessons.

These compelling properties within Kartoon Studios, Inc. (AMEX: TOON)’s IP portfolio highlights the company’s commitment to delivering high-quality, family-friendly content that entertains, educates, and inspires young audiences. By leveraging the star power of renowned personalities like Stan Lee, Arnold Schwarzenegger, Shaquille O’Neal, and Jennifer Garner, Genius Brands continues to expand its IP offerings and engage with a diverse audience base. With an ever-growing portfolio of captivating content, Kartoon Studios, Inc. (AMEX: TOON) is well-positioned for sustained growth and continued success in the dynamic world of children’s entertainment. (6)

GNUS -12
Image Source (11)

The partnership with Shaquille O’Neal not only brings his star power and fan following to Genius Brands, but also leverages his expertise and unique perspective to create compelling programming. With his larger-than-life personality and wide appeal, Shaq adds a valuable dimension to the content portfolio of Genius Brands, further solidifying the company’s position in the children’s entertainment industry. (4)(5)

By partnering with iconic figures like Shaquille O’Neal, Kartoon Studios, Inc. (AMEX: TOON) continues to strengthen its brand offerings, expanding its market reach and engaging with a diverse audience. These strategic collaborations highlight the company’s commitment to delivering high-quality, captivating content that resonates with viewers of all ages.

With the combined force of valuable partnerships, including TOHO Studios, Powerkids Entertainment, and Shaquille O’Neal, Kartoon Studios, Inc. (AMEX: TOON) is poised for continued success in the dynamic world of children’s entertainment. (4)(5)

KARTOON STUDIOS, INC. (AMEX: TOON) BOOSTS GLOBAL REACH AND DISTRIBUTION CHANNELS WITH CONSOLIDATION AND STRATEGIC PARTNERSHIPS (7)

GNUS-13
Image Source (18)

Kartoon Studios, Inc. (AMEX: TOON) has successfully strengthened its distribution channels and expanded its global reach through the consolidation of its consumer platforms under Genius Networks. This strategic move has positioned the company for increased market penetration and audience engagement. (7)

The consolidation includes the ownership of Kartoon Channel!, a highly acclaimed family entertainment destination that has received rave reviews since its launch in 2020. Kartoon Channel! has consistently been recognized as the top customer-reviewed children’s streaming app on the Apple App Store, offering a diverse range of animated classics, educational programming, and original shows like Stan Lee’s Superhero Kindergarten, KC! Pop Quiz, and Shaq’s Garage. Its availability on multiple platforms, such as iOS, Android, Amazon Prime Video, Apple TV, Roku, and Comcast, ensures widespread accessibility for viewers.

In addition to Kartoon Channel!, Genius Brands’ consolidation under Kartoon Studios, Inc. (AMEX: TOON) also encompasses Ameba, a dedicated children’s video streaming service. Ameba focuses on providing active, engaging, and educational programming that sparks curiosity and fosters skill development in children. By featuring a variety of kids TV shows and music videos, Ameba prepares children for school and life while delivering an enriching viewing experience.(7)

Image Source (19)

Another significant component of Genius Networks is Frederator, a pioneering force in streaming video and an independent producer of animation for various platforms. Frederator operates a global animation network on YouTube, boasting a network of over 2000 exclusive creators and influencers. With iconic shows like The Fairly OddParents, Adventure Time, and Bee and PuppyCat in its portfolio, Frederator has established a strong reputation in the animation industry and garners billions of views every month. (7)

Through its strategic partnerships, Kartoon Studios, Inc. (AMEX: TOON) has further enhanced its distribution capabilities and expanded its reach across major digital platforms. Collaborations with notable animation creators on platforms like YouTube, Meta, and TikTok have allowed Genius Brands to tap into diverse audiences and cater to various viewing preferences. Additionally, the acquisitions of WOW! Unlimited Media and Ameba TV have expanded the company’s distribution channels, including the pioneering Ameba TV Amazon Prime Video Channel and SVOD service. (7)

With this comprehensive distribution network in place, Kartoon Studios, Inc. (AMEX: TOON) is well-positioned to reach viewers globally through Ad-Free Subscription VOD (SVOD), Ad Supported VOD (AVOD), and Free Ad-Supported Streaming TV (FAST) channels. Leveraging the popularity and success of its platforms, Genius Brands’ collective digital content offerings generate an impressive average of over 1 billion views per month. (7)

To lead this consolidated network and drive growth, Kartoon Studios, Inc. (AMEX: TOON) has appointed Todd Steinman as the President of Genius Networks. Steinman brings extensive experience in digital media and entertainment, having worked at The Walt Disney Company, Warner Brothers, and WPP. His expertise in operations, content, monetization, and distribution will propel Genius Brands’ mission of providing high-quality and engaging family entertainment across various digital platforms. (7)

With a robust global distribution network, a talented leadership team, and a compelling lineup of family-friendly content, Genius Brands is poised for continued success and growth in the children’s entertainment industry. As the demand for digital content continues to rise, Kartoon Studios, Inc. (AMEX: TOON) is well-equipped to capture the attention of its target audience and solidify its position as a leader in the digital age. (7)

KARTOON STUDIOS, INC. (AMEX: TOON) LAUNCHES CONSUMER PRODUCTS PROGRAM FOR HIT NETFLIX SERIES (8)

GNUS 15
Image Source (20)

Kartoon Studios, Inc. (AMEX: TOON) has announced the launch of its consumer products program for the popular Netflix series, “Bee and PuppyCat,” produced by Frederator Networks. This exciting development comes as Genius Brands signs on new licensing and retail partners to create a range of products targeting tweens, teens, and young adults. (8)

“Bee and PuppyCat” originally gained attention as an animated short and went on to become a highly successful YouTube series on Frederator Network’s Cartoon Hangover Channel. With over 70 million views and a growing fan base of 2.5 million across various social media platforms, the series garnered significant popularity. Capitalizing on this success, Netflix premiered a brand new series called “Bee and PuppyCat Lazy in Space” on September 6, 2022, which quickly topped the “Best New Shows to Watch on Netflix” lists in publications like The New York Times, Forbes, and the LA Times.

To kick off the retail launch, Hot Topic, Inc. recently debuted an exclusive line of “Bee and PuppyCat” apparel online, available on Hot Topic and BoxLunch platforms. These products will also be introduced in select stores later this year. Hot Topic’s VP of Licensing Strategy & Partnerships, Winnie Jaing, expressed confidence in the brand’s appeal and anticipated the line’s expansion beyond apparel.(8)

GNUS 16
Image Source (20)

Kartoon Studios, Inc. (AMEX: TOON) has also secured partnerships with several key licensing partners to create an array of products for the “Bee and PuppyCat” brand. (8)

Sony Music, through its imprint Milan Records, will release the show’s soundtrack globally. BOOM! Studios will produce comics based on the series, while Trends International will offer posters and stickers in the US, Canada, and Mexico.

Toynk will create plush toys for the North American market, while Youtooz will develop collectibles, figures, and plush toys for the US, Canada, Mexico, and the UK. Additionally, Toy Factory will contribute plush toys exclusively for the US and Canada.

Crowdmade has also launched a dedicated online store for “Bee and PuppyCat,” featuring a wide range of merchandise, including apparel, accessories, mugs, posters, plush toys, gifts, collectibles, and home products.

Karen McTier, Licensing Consultant for Genius Brands International, Inc. (Nasdaq: TOON), highlighted the tremendous demand for “Bee and PuppyCat” products and expressed excitement about the brand’s expanding consumer products program. As Genius Brands heads into the Licensing Expo in June, the company aims to explore additional categories such as stationery, publishing, home goods, hardlines, footwear, gaming, electronics, and more. They also plan to pursue promotional partnerships and collaborations to further extend the brand’s reach.

As Kartoon Studios, Inc. (AMEX: TOON) continues to expand its portfolio, the partnership with TOHO International, who acquired a 50% stake in “Bee and PuppyCat,” further enhances the global reach of the property. Genius Brands’ consumer products team will manage the worldwide consumer products program for “Bee and PuppyCat,” excluding Asia, which will be handled by TOHO International.(8)

With the launch of the consumer products program and the enthusiastic response from licensing partners and retailers, “Bee and PuppyCat” is poised to become a beloved brand among fans worldwide. The success of the series, coupled with the expanding consumer products program, sets the stage for even greater opportunities and engagement with the “Bee and PuppyCat” franchise.

NEWS

KARTOON STUDIOS ANNOUNCES ‘STAN LEE COMICS’, BASED ON NEVER-BEFORE-RELEASED STORIES AND CHARACTERS CREATED BY STAN LEE

Jul 11, 2023

KARTOON STUDIOS’ PREMIERE OF SHAQ’S GARAGE, STARRING SHAQUILLE O’NEAL, OUTPERFORMS DURING JUNE EXCLUSIVE ON PLUTO TV

Jul 10, 2023

KARTOON STUDIOS ANNOUNCES THE WORLD PREMIERE OF “EXCELSIOR! THE LIFE AND LEGACY OF STAN LEE” EXHIBITION

Jun 27, 2023

KARTOON STUDIOS CHAIRMAN & CEO TO APPEAR LIVE ON THE CLAMAN COUNTDOWN ON FOX BUSINESS NETWORK TODAY

Jun 26, 2023

KARTOON STUDIOS TRANSFERS LISTING TO NYSE AMERICAN – BEGINS TRADING UNDER NEW TICKER SYMBOL ‘TOON’

Jun 26, 2023

BUZZFEED ANIMATION LAB TO DEVELOP NEW ANIMATED SERIES “CHIKN NUGGIT” WITH GENIUS BRANDS’ FREDERATOR NETWORK, INC.

Jun 20, 2023

GENIUS BRANDS ANNOUNCES THE JUNE 16 PREMIERE OF THE STAN LEE DOCUMENTARY ON DISNEY+

Jun 15, 2023

GENIUS BRANDS ANNOUNCES NAME CHANGE TO ‘KARTOON STUDIOS’; SET TO TRANSFER LISTING TO NYSE AMERICAN UNDER NEW TICKER SYMBOL, ‘TOON’

Jun 13, 2023

KARTOON CHANNEL!’S “SHAQ’S GARAGE,” DELIVERS TOP RANKINGS FOR ITS JUNE 5 PREMIERE ON PLUTO TV

Jun 13, 2023

GENIUS BRANDS’ KARTOON CHANNEL! WORLDWIDE PARTNERS WITH POWERKIDS ENTERTAINMENT IN INDIA TO LAUNCH A NEW CO-BRANDED ENTERTAINMENT DESTINATION, “POWERKIDS KARTOON CHANNEL!”

GENIUS BRANDS ANNOUNCES APPOINTMENT OF HENRY SICIGNANO III TO THE BOARD OF DIRECTORS

May 26, 2023

GENIUS BRANDS ANNOUNCES SLATE OF INTERNATIONAL CONTENT SALES IN EUROPE, LATIN AMERICA & ASIA PACIFIC

May 25, 2023

GENIUS BRANDS AND ANDAMIRO USA TO RELEASE THE FIRST EVER “SHAQ’S GARAGE” ARCADE GAME THIS SUMMER NATIONWIDE

May 24, 2023

GENIUS BRANDS LAUNCHES CONSUMER PRODUCTS PROGRAM FOR ITS FREDERATOR NETWORK’S GLOBAL PHENOM AND NETFLIX SERIES, “BEE AND PUPPYCAT”

May 23, 2023

GENIUS BRANDS ANNOUNCES 885% INCREASE IN REVENUE FOR Q1 2023

May 22, 2023

GENIUS BRANDS FILES FORM 10-K ANNUAL REPORT

Apr 13, 2023

GENIUS BRANDS CEO ANDY HEYWARD AND SHAQUILLE O’NEAL TO APPEAR LIVE TODAY AT 12:45 PM ET ON BLOOMBERG TELEVISION TO DISCUSS UPCOMING PREMIERE OF “SHAQ’S GARAGE”

Apr 4, 2023

KARTOON CHANNEL!’S “SHAQ’S GARAGE,” STARRING SHAQUILLE O’NEAL, TO PREMIERE EXCLUSIVELY ON PLUTO TV

Apr 3, 2023

GENIUS BRANDS ANNOUNCES 691% INCREASE IN REVENUE FOR 2022

Apr 3, 2023

GENIUS BRANDS TO RELEASE NEW WARREN BUFFETT’S SECRET MILLIONAIRES CLUB MINIS, PRODUCED BY GENIUS AI STUDIO

Mar 2, 2023

MANAGEMENT TEAM

Andy Heyward

ANDY HEYWARD

Chairman & Chief Executive Officer

Emmy Award-winning Andy Heyward has made more episodes of kid’s television than any other producer.  After graduating from UCLA with a Bachelor of Arts degree in Philosophy in 1975, he joined Hanna-Barbera as a writer and story editor.  During his five years with Hanna-Barbera, he was involved in the development and writing of numerous series including Scooby Doo, Flintstones, Jetsons, Smurfs, Yogi Bear and Scooby’s All Star Laff-A-Lympics.  In 1980 he moved to France where he joined DIC Audiovisual, a production company specializing in children’s animated programming.  In 1982, he co-created Inspector Gadget and during the following years he has produced over 5,000 episodes of award-winning children’s programs, most of which shows and brands are household names, including Inspector Gadget, The Real Ghostbusters, Alvin and the Chipmunks, G.I. Joe, Hello Kitty, Sonic the Hedgehog, Super Mario Bros, Sabrina the Teenage Witch, Strawberry Shortcake, Care Bears, Captain Planet, Teddy Ruxpin, Sailor Moon, Madeline, Where on Earth is Carmen Sandiego, Liberty’s Kids, and dozens more.  In 1994, he convened the National PTA, National Education Association, UCLA and producers from throughout the industry to draft the first voluntary set of program guidelines for children’s television.  In 1996, he hosted the first meeting between then FCC Chairman Reed Hundt and children’s television producers.

Today under Kartoon Studios, Heyward produces and licenses brands ranging from Stan Lee Universe, to Baby Genius, to Warren Buffett’s Secret Millionaires Club, to Thomas Edison’s Secret Lab, to SpacePop for the global market.  He has also been the largest producer of FCC mandated educational informational programming for children, and has produced hundreds of PSAs promoting child safety, health, exercise, and nutrition.  In collaboration with Warren Buffett, he produces the short film which opens the annual Berkshire Hathaway Shareholders meeting, and he co-authored a book with Warren Buffett promoting financial literacy for kids.  Heyward is also the author of Go Go Gadget – The Creation of Inspector Gadget.

Andy’s notable work in children’s programming has earned him multiple industry awards, and his charitable efforts off-screen have resulted in numerous recognitions. Some of his awards include two Emmys, nine Emmy nominations, two Humanitas Awards, two Cable Ace Awards, five Golden Reel Awards, three Environmental Media Awards, a New York Television Festival Award and a National Education Association Award, among others.  He was inducted into the KidScreen Hall of Fame, and won the Studio of the Year at Italy’s Cartoons on the Bay International Festival of Television Animation in 2006 (co-awarded to Roy Disney).

Heyward is a member of the Producers Guild of America, the National Academy of Television Arts and Sciences, the International Academy of Television Arts and Sciences, and the British Academy of Film and Television Arts (BAFTA).  He was the 2010 UCLA College of Humanities Commencement speaker and is currently a Mentor in the UCLA mentoring program.  He is active in many community activities, including serving on the Board of Directors of Cedars-Sinai Medical Center.

Margaret Loesch

MARGARET LOESCH

Executive Chairman Kartoon Channel!

Throughout her formidable career, Margaret Loesch has held senior roles with numerous leading companies as both a creative and business executive. In 1990, she became the founding President and CEO of Fox Kids Networks Worldwide, growing the channels across all metrics, where it was eventually sold to the Walt Disney Company for $5.5 billion. During this time, she launched a multitude of hit series, including the billion-dollar brand Power Rangers, growing Fox Kids into the top children’s program service on television.

Prior to Fox Kids, Loesch served as President & CEO of Marvel Productions. Previously, she was President of The Jim Henson Company, and the Founding President & CEO of the U.S. Hallmark Channel and Crown Media U.S. Most recently, Loesch served as President of the HUB, which was a joint venture between Hasbro Toys and Discovery Communications, where she had oversight of all business and creative areas of the network. In addition to Power Rangers, her resume includes launching some of the most successful animated children’s properties in the world, such as Batman, Spider-Man, Steven Spielberg’s Animaniacs, Transformers, My Little Pony, X-Men, Muppet Babies, and Fraggle Rock.

David Neuman

DAVID NEUMAN

Chief Creative Officer

David Neuman’s 30-year career spans television, film, and digital media, where among other executive roles, he was President of Walt Disney Television and Touchstone Television where he oversaw hits such as The Wonderful World of Disney, Boy Meets World, Ellen, and the then #1 sitcom on television, Home Improvement. As VP of Comedy at NBC, Neuman oversaw iconic series, such as Cheers, Family Ties, Golden Girls, and Alf, where during his tenure, NBC series received over 100 Emmy Awards. He has also served as Chief Programming Officer for CNN, a TV and film producer at 20th Century Fox, and founding exec/head of content at three landmark startups: Channel One, Digital Entertainment Network, and Current TV. Along the way, Neuman was instrumental in launching the careers of Anderson Cooper, Lisa Ling, and Jason Silva, among many others.

Michael Jaffa

MICHAEL JAFFA

Chief Operating Officer

Michael Jaffa served as Head of Business Affairs at DreamWorks Animation Television and was responsible for all studio business and legal affairs matters, including the negotiation and drafting of hundreds of development, production, acquisition, talent, digital and music agreements. Previously, he was the Vice President of Legal & Business Affairs for Hasbro Studios, working directly with Hasbro Studios’ President, CFO, and General Manager to help create programs and launch strategy for a new studio and related network. Michael has also represented various clients, including Sony Pictures Animation and MGM Studios. Michael received a J.D. from New York University School of Law.

Robert Denton

ROBERT DENTON

Chief Financial Officer

Robert Denton has spent the past six years in the role of CFO/Controller for Atlys Inc., a next-gen media technology company. His entertainment experience includes assisting with the restructuring of corporate financing for Gold Circle Films, a theatrical motion picture production and distribution company, as its interim chief financial officer; five years as CFO of DIC Entertainment Corp., the global brand management, production and distribution company specializing in family entertainment with annual sales of $85 million. Other previously held executive positions include Chief Operating Officer at Artisan Home Entertainment; Vice President of Finance for LIVE Home Video and VP, Chief Accounting Officer of LIVE Entertainment. He got his professional start with Ernst & Young’s Century City office most recently as a Senior Manager.

Denton, a graduate of California State University, Northridge, with a BS degree in Business Administration-Accounting, Denton is a Certified Public Accountant in the State of California as well as a member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants.

Jon Ollwerther

JON OLLWERTHER

Executive Vice President

Ollwerther joins Kartoon Studios from Measure, the nation’s leading Drone as a Service® company.  As Vice President of Media, Ollwerther grew the Arts & Entertainment division from its inception and worked with leading media companies and advertisers like ABC, CBS, ESPN, Red Bull Media House, Coach, Prada, Maker’s Mark, and Nissan.

As a trailblazer in an emerging industry, Ollwerther focused on leveraging drones as a tool for artistic expression and informational use, including major franchise films to live concerts and events. Among other accomplishments, he pioneered live broadcasting via drone for news and sports and spearheaded the first live drone network broadcasts in America, and helped bring drone light shows to life.  Working with clients across the country and around the world, Ollwerther has an extensive credit list of collaborations with brands and advertising agencies to create unforgettable experiences. Prior to joining Measure, Ollwerther was the COO of an aerial robotics company based in NYC.

Lloyd Mintz

LLOYD MINTZ

Senior Vice President, Head of Worldwide Consumer Products

Lloyd Mintz is a seasoned industry executive with more than 20 years of experience in licensing, merchandising and new business development and is widely respected for his expertise in leveraging brand equity through licensing. He works with retailers and licensees to build comprehensive global consumer products’ programs for each of the company’s brands. Prior to Kartoon Studios, Lloyd managed his own consultancy during which time he negotiated more than 150 licensing agreements and generated over $700MM in cumulative retail sales on behalf of clients across a range of brand owners and manufacturers. Most recently, he worked as Executive Vice President of Licensing for NYC-based Galaxy Brands that owned the AND1 and AVIA athletic brands. Previously, Lloyd worked at Hasbro, Inc. as the Vice President of Domestic Corporate Licensing where he pioneered the effort to license Hasbro’s classic game brands, such as Monopoly, to slot machine manufacturers. He began his licensing industry career at Disney Consumer Products where he oversaw Disney’s largest licensee, Mattel, Inc., and their development of toy programs for classic properties such as Lion King, Winnie the Pooh, and Aladdin. Lloyd graduated from Wesleyan University and earned his M.B.A. from UCLA’s Anderson School of Management.

Michael Hirsh

MICHAEL HIRSH

CEO of Mainframe Studios and Director

Since April 2022, Michael Hirsh has served as Chief Executive Officer of Mainframe Studios, a Canadian-related entity of the Company. Mr. Hirsh served as Chief Executive Officer of WOW! Unlimited Media Inc. (“Wow”) from December 2016 until April 2022, when the Company acquired Wow. Prior to Wow, Mr. Hirsh founded and was CEO of Cookie Jar which he merged with DHX Media(now Wild Brain) where he served as Executive Chairman from 2012 to 2015. Mr. Hirsh was also a co-founder and CEO of Nelvana from 1971 to 2002 where he developed and produced numerous award-winning productions including, The Magic School Bus, Care Bears, Babar, Rupert, Beetlejuice, The Adventures of Tintin and created the first Star Wars animated series with George Lucas. Mr. Hirsh has won Daytime Emmy Awards, Gemini Awards, the Joe Shuster Award, and a Golden Reel Award.

Cindy Kelly

CINDY KELLY

President of Beacon Media Group

Kelly joins Kartoon Studios with over 25 years of experience in executive sales and sponsorship roles at leading media companies, including extensive children’s media sales at Cartoon Network. She also served as Broadcast Account Supervisor at Ogilvy & Mather Advertising in NYC, overseeing media strategy for blue chip accounts, including, Mattel Toys, Campbell’s Soup and Paramount Pictures.

Todd Steinman

TODD STEINMAN

President of Toon Media Networks

Todd Steinman is an accomplished growth marketing executive who with extensive B2B and B2C experience.  Prior to joining Kartoon Studios, Steinman most recently served as Vice President in the Direct to Consumer and International division at The Walt Disney Company, which included Disney+ during its launch. He helped create solutions to leverage the Walt Disney Company’s portfolio of linear and digital brands, including DISNEY, HULU, ESPN, ABC, FREEFORM, FX, and Nat Geo, while setting strategy for ad sales and revenue teams. Prior to his role at The Walt Disney Company, Steinman co-founded the digital media agency, M80, and then led the NBC Universal media team for WPP after they acquired M80. He negotiated multi-million-dollar annual media deals with Google/YouTube, Amazon, Hulu, Disney, Twitter, Snapchat, Spotify, and others, while managing an annual budget north of $1 billion.

Paul Robinson

PAUL ROBINSON

President of Kartoon Channel! Worldwide

Paul Robinson is an accomplished and seasoned media executive with significant experience developing media brands around the globe. Robinson previously served as Managing Director of Disney Channel Worldwide, where he was responsible for global programming and production strategy. He also founded the Toon Disney and Playhouse Disney television channels internationally. Before his tenure at The Walt Disney Company, Robinson was Head of Strategy for the BBC Newtork Radio, overseeing the strategy development for BBC Radios 1, 2, 3, 4, and 5 Live. Additionally, he has served as Managing Director of talkSPORT; Co-Founder and CEO of KidsCO, NBCUniversal’s international children’s channel; and Executive Vice President of Your Family Entertainment AG, in which Kartoon Studios recently acquired a controlling stake.

Sources:

Source 1: https://finance.yahoo.com/news/genius-brands-announces-885-increase-130000171.html
Source 2: https://dawsonjames.com/wp-content/uploads/2023/05/Gnus-2023-05-24-Q1-Results-v1-final1.pdf
Source 3: https://www.barchart.com/stocks/quotes/GNUS/price-history/historical?orderBy=tradeTime&orderDir=desc
Source 4: https://www.gnusbrands.com/news/press-releases/detail/1176/toho-international-makesmulti-million-dollar-investment
Source 5: https://finance.yahoo.com/news/genius-brands-kartoon-channel-worldwide-130000747.html
Source 6: https://content.equisolve.net/sec/0001355848-23-000015/gnus-20230331.htm#ifd6e94bfb1f64ba694685191cef909d4_7
Source 7: https://www.gnusbrands.com/news/press-releases/detail/1179/genius-brands-consolidates-consumer-platforms-under-newly
Source 8: https://www.globenewswire.com/en/news-release/2023/05/23/2674401/0/en/Genius-Brands-Launches-Consumer-Products-Program-for-Its-Frederator-Network-s-Global-Phenom-and-Netflix-Series-Bee-and-PuppyCat.html
Source 9: https://schrts.co/sipQzEUw
Source 10: https://pbs.twimg.com/media/FCtpwV3VgAc-MJQ.jpg
Source 11: https://deadline.com/wp-content/uploads/2020/10/shaquille-oneal-from-genius.jpg
Source 12: https://deadline.com/wp-content/uploads/2022/12/streaming-ahead.jpg?w=1280&h=720&crop=1
Source 13: https://www.anbmedia.com/wp-content/uploads/2022/05/Genius-Brands-Stan-Lee.png
Source 14: https://cdn.mos.cms.futurecdn.net/Taob2mjWZzUeNE5ctMCV6Z.jpg
Source 15: https://twitter.com/GNUSBrands
Source 16: https://m.imdb.com/name/nm0382375/news/
Source 17: https://www.totallicensing.com/wp-content/uploads/2021/10/ArnoldS_with_Emerson-hi-res-v1a.jpg
Source 18: https://www.cnet.com/tech/home-entertainment/apples-tv-app-is-on-roku-fire-tv-and-samsung-but-only-apple-devices-get-every-feature/
Source 19: https://frederatornetworks.frederator.com/
Source 20: https://media.wired.com/photos/5a99bfb59308984e6405325c/master/w_2560%2Cc_limit/FEATURED-Netflix-_MG_5752.jpg
Source 21: https://static1.thegamerimages.com/wordpress/wp-content/uploads/2022/08/bee-and-puppycat.jpg
Source 22: https://schrts.co/FBqxYxKE

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIXTEEN THOUSAND USD BY A THIRD PARTY, TD MEDIA LLC FOR A ONE DAY TOON AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

Nasdaq: MGRX Profile

Mangoceuticals, Inc. logo

OUR NEW PROFILE IS: (NASDAQ: MGRX)

52% of men experience some form of erectile dysfunction throughout their life and that total increases anywhere from 5-15% between ages 40 and 70

Mangoceuticals Signs Deal with BarStool Sports to Market Mango on Popular “Only Stans” Podcast

Mangoceuticals, Inc.’s Debut Commercial Surpasses 7 Million Views on YouTube

Hello Everyone,

We are looking to bounce back after that last profile with something brand new that we have never brought to your attention.

This is a company that just started trading back in March and has found a trading range after its initial IPO.

The company just started making some major announcements and its initial marketing video has surpassed 7 million views on YouTube.

Pull up MGRX immediately.

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think “Man Go”).

Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online telehealth visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.

MangoRx recently concluded its successful IPO on the Nasdaq Capital Market, generating $5,000,000 in gross proceeds. These funds will be utilized to finance marketing and operational expenses related to the planned launch of their flagship Mango product. Additionally, the proceeds will support talent acquisition, software development, and general corporate purposes.

Mangoceuticals is making waves in the men’s health market with its innovative approach and commitment to redefining the standards for ED treatment. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers.

The men’s health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men’s health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.

The men’s health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs. These offerings cater to various aspects of men’s health, including physical fitness, mental wellness, and nutritional support.

Beyond product offerings, Mangoceuticals understands the importance of education and information in men’s health. MangoRx is dedicated to providing comprehensive knowledge and resources, empowering men to make informed decisions about their well-being. By sharing information confidently and breaking down barriers, Mangoceuticals is destigmatizing the conversation around men’s health.

MangoRx offers a convenient telemedicine platform, allowing men to access their products without leaving their homes. By eliminating the need for in-person doctor visits, MangoRx provides a discreet and accessible solution for men’s health needs. With a streamlined process, users can create an account, complete a telemedicine session, and have their prescribed products delivered to their doorstep.

The MangoRx approach differs from other ED treatments in its commitment to education and refreshing approach to the topic. While the subject matter is serious, MangoRx embraces a fun and confident attitude. By injecting humor into their brand, they aim to empower men on their journey to better health, ensuring that the pursuit of ‘intimate well-being’ is an enjoyable experience.

Mango (Man-Go)

Mango, Mangoceuticals’ flagship product, is a groundbreaking solution designed to address men’s unique concerns. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.

Mango stands out with its rapid-dissolving mango-flavored tablets, which deliver quicker results by efficiently entering the bloodstream. These sublingual Rapid Dissolving Tablets (RDTs) contain the same active ingredient as Cialis (tadalafil), as well as the MGRX unique blend. By incorporating this combination, Mango offers a tasty, efficient, and powerful solution for men seeking faster relief from the symptoms of ED.

Earlier this month, MGRX announced via Twitter that Mango is now available in Nevada. This expansion marks a significant milestone for Mangoceuticals as they continue to broaden their market reach and offer their cutting-edge men’s health and wellness products to new potential customers.

Mango is now available in 44 states, including Nevada and the District of Columbia.

Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Dallas, Texas, June 21, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,”, is pleased to announce the upcoming release of its second Mango ED product leveraging the Company’s existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra™.

The launch of the Company’s Sildenafil based Mango ED product is scheduled to be available for purchase online this summer. Like the Company’s currently marketed and sold Tadalafil based Mango ED product, which leverages the same active ingredient found in Cialis™, the new Sildenafil-based Mango will still be compounded with Oxytocin and L-Arginine in a tasty Mango-flavored rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.

“Our intent with the launch of this new product is to establish Mango as a legitimate competitor armed with the biotechnology behind Tadalafil and Sildenafil, both of which are the two runaway winners in the ED space over the past two decades,” noted Jacob Cohen, CEO and Co-Founder of MangoRx. “The ED market has already proven to be big enough to accommodate multiple competing products. Some people like Pepsi and others prefer Coca-Cola. Tadalafil and Sildenafil are both effective biotech solutions and we believed it was important to make both options available in order to capture additional market share and not exclude potential customers based on personal preferences.”

Management also notes that Tadalafil and Sildenafil each have their own unique properties, which can lead to different manifest effects among users. For example, Tadalafil has been proven to last longer than Sildenafil due to a half-life more than four times as long. At the same time, Sildenafil may reach full efficacy faster than Tadalafil. But the most important point is that each has cultivated its own sizeable following and both compounds can be effectively integrated into MangoRx’s specialty compounded formula.

Management is also very encouraged by the buzz generated through its recently expanded marketing activities.

Cohen concluded, “We are extremely pleased with our recent efforts and sponsorships with Barstool Sports and GaS Digital Networks and we only intend to get more aggressive with our marketing efforts in the upcoming months as we market our new Sildenafil based Mango ED product. There’s a real buzz and it’s growing. That sense should be amplified further by additional new products that we intend to launch in the upcoming months. Overall, it’s an exciting time for the Company, and we have a lot more excitement to come as we continue to focus on taking market share through the further development of innovative product formulas, superior branding, marketing initiatives and product design.”

Mangoceuticals Signs Deal with BarStool Sports to Market Mango on Popular “Only Stans” Podcast

Dallas, Texas, June 08, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce that it has been engaged as a new sponsor for Barstool Sports’ “ Only Stans ” podcast ( barstoolsports.com/shows/39956939/only-stans ).

“We couldn’t be more excited to have the opportunity to sponsor the hugely popular Only Stans podcast,” stated MGRX Co-Founder and CEO, Jacob Cohen. “It isn’t easy to find, land, and execute a sponsorship this on-target from a branding perspective. This is a wildly popular podcast with a massive audience that resonates especially well with our target market. And we are thrilled to have access to that audience to help them truly appreciate our product benefits.”

The Only Stans podcast, “the world’s first Only Fans show by the world’s first Only Fans journalist”, averages more than 320,000 listeners per episode. The Company plans on sponsoring at least 8 episodes over the next two months, with more brand involvement potentially in the works. Company representatives believe this strategy has the potential to generate substantial new interest among both customers and prospective investors.

“The idea here is simple,” added Cohen. “We are aligning ourselves with BarStool Sports, which is a nationally recognized brand that has a rock-solid track record in terms of appealing to a male audience and has a massive market footprint and overall audience size. Through that process, we are sponsoring the ‘ Only Stans ’ podcast, which appeals to our sexually active target audience. And we also want our shareholders to know that we are serious about growth-oriented marketing, and we will be aggressively hunting additional sponsorship deals with similar media opportunities in the future on Barstool as well as other similar platforms.”

Mangoceuticals, Inc.’s Debut Commercial Surpasses 7 Million Views on YouTube

Mangoceuticals, Inc. (MGRX) Commences Online Direct Sales Campaign Utilizing DataDojo AI and Customer Data Platform (CDP)

Utilizes AI powered customer segmentation to determine best customers through analysis of 400+ attributes per customer profile

DALLAS, TX / ACCESSWIRE / April 25, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce that it has commenced an online sales campaign with DojoLabs Group, Inc. (“DataDojo”), utilizing their proprietary Customer Data Platform (“CDP”), and an AI powered, deep learning identification, segmentation, and conversion optimization technology, and a database of over 240 million U.S. consumer profiles used to identify and acquire online customers.

Per the terms of a consulting agreement entered into with DataDojo on January 3, 2023, MangoRx has been working with DataDojo to design and develop a custom infrastructure to support MangoRx’s scalable direct response online sales campaign. This included i) the development and design of custom direct response landing pages, ii) sales funnel planning and development, iii) media content development and production, iv) development of email marketing and retargeting assets, v) strategic e-commerce eco-system planning, vi) product upsell strategies and shopping cart experiences, and vii) the multi-channel media setup, integration and activation of the DataDojo CDP.

In addition, the DataDojo agreement provided MangoRx with a pre-loaded database consisting of 5 million consumer profiles and records for MangoRx’s marketing and outreach, leading to lower overall customer acquisition costs.

“We are very excited to be working with DataDojo, whose team and founders are proven experts in marketing technology and e-commerce with over $1 billion generated in direct-to-consumer online sales through the use of their Customer Data Platform,” commented Jacob Cohen, CEO and Co-Founder of MangoRx, who continued, “As MangoRx is seeking to rapidly expand its consumer base nationwide, we believe the use of DataDojo’s AI tools and CDP can play a significant part in increasing our online sales, while maximizing our marketing spend efficiencies.”

Robert Tallack, CEO and Co-Founder of DataDojo commented, “DataDojo specializes in converting website visitors into rich 1st party data. According to McKinsey & Company, companies that use 1st party data can reduce customer acquisition costs (CAC) by up to 50% and increase revenues from between 5 and 15%. DataDojo prides itself in capturing and leveraging 1st party data to build detailed customer profiles. In our experience profile driven retargeting can lead to an average of 5x media returns on investment (ROI) and increased profit. DataDojo is successfully running on 90+ e-commerce stores and we are excited to apply the technology and our expertise to work to achieve increases in sales for MangoRx.”

NEWS

  • ACCESSWIRE•11 days agoMangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce its new collaboration with Ice Shaker to supply custom-made Mango-branded Ice Shaker bottles to be sold exclusively on the company’s new MakeAmericaHardAgain.com
  • GlobeNewswire•13 days agoMangoceuticals Launches “Make America Hard Again” Campaign & Merchandise WebsiteDallas, Texas, June 27, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce the launch of its new “Make America Hard Again” nationwide marketing campaign and website, www.MakeAmericaHardAgain.com. The newly launched Ma
  • GlobeNewswire•18 days agoMGRX’s CEO, Jacob Cohen returns to the Nasdaq MarketSite Studio to begin filming a Multi-Part TV Series with New to The Street discussing MangoRx Dallas, Texas, June 22, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,”, is pleased to announce t
  • GlobeNewswire•19 days agoDallas, Texas, June 21, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,”, is pleased to announce the upcoming release of its second Mango ED product leveraging the Company’s existing custom compound alongside Sildenafil, which is the active ing
  • GlobeNewswire•25 days agoMangoceuticals continues to increase its marketing of Mango & corporate visibility, jointing many well-known podcasts in the epicenter of uncensored and unfiltered comedy Dallas, Texas, June 15, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Ma
  • GlobeNewswire•last monthMangoceuticals Signs Deal with BarStool Sports to Market Mango on Popular “Only Stans” PodcastDallas, Texas, June 08, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce that it has been engaged as a new sponsor for Barstool Sports’ “Only Stans” podcast (barstoolsports.com/shows/39956939/only-stans). “We couldn
  • GlobeNewswire•2 months agoMangoceuticals Adds Renowned Tech Entrepreneur and Investor, Aaron Andrew, to Advisory BoardDallas, Texas, May 25, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce that it has added serial technology entrepreneur and investor, Aaron Andrew, to its advisory board (the “Advisory Board”). On January 5, 2023,
  • GlobeNewswire•2 months ago

MANAGEMENT

Photo of Jacob Cohen

Jacob Cohen

Co-Founder and Chief Executive Officer

Jacob Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising, healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of debt and/or equity and in both private and public markets.

Prior to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer, wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller of Metiscan, Inc., a publicly traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded the company’s financial audit process and managed its various filings with the SEC.

From 2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts in International Economics and Finance from Brandeis University in Waltham, Massachusetts.

Mr. Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman from September 2022 to present. Mr. Cohen also currently serves as Chief Executive Officer and as a director of American International Holdings Corp (“American International”), a publicly traded company which is the majority owner and parent to Epiq Scripts, LLC, and which is the former sole owner of the Company, having fully divested its ownership in June 2022, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013.

Jonathan Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical & health, restaurants, and cryptocurrency.

Photo of Jonathan Arango

Jonathan Arango

Co-Founder and President

Mr. Arango has served as the Co-Founder, President and Director of the Company since October 2021. Prior to his appointment to the Company, Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting, a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019. He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.

Before entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&J Marketing). A&J Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple sectors. Industries included were Home Improvement, Oil & Gas, Health & Wellness, Professional Development, and E-commerce.

Photo of Amanda Hammer

Amanda Hammer

Chief Operating Officer

Amanda Hammer has been a member of the MangoRx team since late 2022 and has been instrumental in launching and optimizing MangoRx’s eCommerce platform. She is a proven leader with a track record of success having recently completed a 4-year tenure at D Magazine Partners, a Dallas based multimedia company, where she held roles leading Audience Development, Brand, and Digital Operations, quickly rising to become the company’s first named Chief Operations Officer. Prior to that, Amanda worked in private equity consulting and assisting newly acquired business verticals with optimizing sales and marketing processes, improving subscription retention, and training new talent to enhance productivity and maximize revenue streams.

Amanda obtained dual Bachelor of Arts degrees—in Graphic Design and Communication Studies—from the University of Iowa. She has also obtained a Negotiation and Leadership Certificate from Harvard Law School and is a recent graduate of the Texas Women’s Foundation Leadership Institute.

Photo of Eugene M. Johnston

Eugene M. Johnston

Chief Financial Officer

Mr. Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr. Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January 1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products company.

Mr. Johnston received a Bachelor’s in Science in Business Administration from the University of North Carolina Charlotte.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, BULLZEYE MEDIA LLC FOR A ONE DAY MGRX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(NASDAQ: PBTS) Profile

OUR NEW PROFILE IS:  (NASDAQ: PBTS)

   _________________

PBTS HAS OVER 300 EMPLOYEES 

MORE THAN 1600 COMPANIES TRUST US TO HELP THEM STREAMLINE THEIR OPERATIONS, IMPROVE INTER-DEPARTMENTAL EFFICIENCY, AND REDUCE OPERATIONAL OVERHEAD

POWERBRIDGE TECHNOLOGIES ACQUIRES AIEDU, UNLOCKING NEW AVENUES FOR CHATGPT APPLICATIONS

POWERBRIDGE TECHNOLOGIES ANNOUNCES STRATEGIC JOINT VENTURE TO DRIVE DIGITAL FINANCIAL INNOVATION FOR AGRICULTURE AND LIVESTOCK INDUSTRIES

Hello Everyone,

We have a new Nasdaq profile that we wanted you to look at for tomorrow’s session.  This is a company operating in THE hottest sectors on Wall Street right now.

Pull up PBTS right away.

PBTS is a leading provider of multi-industry technology solutions. The Company offers software and platform applications, IoT platform services and intelligent devices, supply chain platforms and interactive media services, metaverse and digital services, and cryptomining platform services and cryptocurrency asset operations.

With everyone talking about ChatGPT and AI right now, PBTS stands to gain some recognition as the operate in the Artificial Intelligence space as well as the Metaverse, Crypto and other Fintech areas.

The Chairman Shiang Lor made a big insider purchase in the past year. That single transaction was for US$2.3m worth of shares.  Clearly the chairman is putting his money where is mouth is and is bullish on the company.  This was pre-consolidation!

Powerbridge’s smart monitoring system is powered by AR, IoT and AI, and incorporates the Beidou Navigation System. As the company said, the platform enables smart monitoring and control, embedded management, and automatic clearance of goods at a variety of cross-country borders where highly regulated trading and operations take place.

Today, the platform is used at a number of ports in Guangxi province, and that alone has generated Powerbridge more than $2.4 million in revenues, according to the company’s statement. And it expects a surge in revenues over the coming years amid a favorable environment spurred by government support and strong interest for its product, as well as rising import and export trade. Specifically, Powerbridge projected revenue growth from its Smart Monitoring Platform of more than $15 million over the next two-to-three years.

Powerbridge also highlighted some improvements that its SMP clients were able to achieve: 37% clearance time reduction of vehicles and 47% increase in the volume of imported goods. In addition, the efficiency of customs inspection has improved by 40% while the labor requirement has reduced by 50%, the company said.

“We have been offering our customers complete solutions, proposing a more efficient way of intelligent surveillance and operations and seamless inspection as well,” Powerbridge President Stewart Lor said in the statement today. “At the same time, we have been devoting ourselves to ensuring effective operations of customs clearance of goods throughout the entire process for all the border trade participants.”

Powerbridge has been providing global trade services for more than two decades. While the company has diversified into Bitcoin mining and developing smart city and metaverse solutions for travel and leisure industries, the cross-border trade segment has remained its core business. Earlier this month, Lor shared in an interview that Powerbridge has scored $5 million worth of contracts on digitization solutions for some new and existing clients in the trade logistics space.

POWERBRIDGE TECHNOLOGIES CO., LTD. ANNOUNCES SHARE CONSOLIDATION

ZHUHAI, China, June 8, 2023 /PRNewswire/ — Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (the “Company” or “Powerbridge“), a provider of multi-industry technology solutions, today announced the closing of its 1-for-30 share consolidation of its ordinary shares (the “Share Consolidation“) effective immediately after the close of trading on Nasdaq Capital Market on June 8, 2023, and the Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of trading on June 9, 2023. At market open on June 9, 2023, the Company’s ordinary share will continue to be traded on the Nasdaq Capital Market under the symbol “PBTS” with the new CUSIP number G72007118. The Company undertook the Share Consolidation to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) related to the $1.00 per share minimum price bid requirement for continued listing on the Nasdaq Capital Market.

As a result of the Share Consolidation, every thirty shares of the Company’s issued and outstanding ordinary shares will be automatically consolidated into one new ordinary share. The Share Consolidation will not modify any rights of the ordinary shares of the Company. No fractional shares will be issued in connection with the Share Consolidation, all such fractional shares shall be redeemed in cash for the fair value of such fractional share, which is based on the closing price of the ordinary shares on a post-consolidation basis on the Nasdaq Capital Market on the first trading date of the ordinary shares following the Share Consolidation.

Additional information about the Share Consolidation can be found in Powerbridge’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC“) on April 25, 2023, which is available free of charge at the SEC’s website, www.sec.gov, and on Powerbridge’s Investor Relations website at https://www.powerbridge.com/ir/.

POWERBRIDGE TECHNOLOGIES ACQUIRES AIEDU, UNLOCKING NEW AVENUES FOR CHATGPT APPLICATIONS

ZHUHAI, China, April 4, 2023 /PRNewswire/ — Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a leading provider of multi-industry technology solutions, today announced it has acquired 90% stake of Ascendent Insights Education Co., Ltd. (“AIedu”), an AI education service company. This move is part of Powerbridge’s strategy to expand its presence in the education industry and leverage AIedu’s expertise to further improve its offerings.

The acquisition of AIedu will enable Powerbridge Technologies to integrate ChatGPT into its existing education offerings, one of the key drivers of growth for the Company. ChatGPT is a game-changing product in early childhood education that provides personalized learning experience for students. The integration of ChatGPT into Powerbridge’s existing education offerings is expected to create substantial benefits for the Company, including expanded market opportunities, a larger user base, and increased revenue streams.

“Joining forces with Powerbridge will help us to provide our AI-powered education services to a larger base of participant more students,” said Aaron Liu, CEO of AIedu. “We are excited to work with Powerbridge to integrate our innovative products and further develop cutting-edge solutions that meet the needs of pre-childhood education. Our team is excited to bring continued values to the company.”

Stewart Lor, CEO of Powerbridge Technologies, commented: “The acquisition of AIedu is an exciting step forward as the Company continues to innovate and bring cutting-edge technology services to the education industry. With our focus on personalized learning experiences for pre-school children, we are well-positioned to tap into this growing market and drive future growth for our shareholders.”

About Ascendent Insights

AIedu is an AI education service company with more than 400,000 users and over 20,000 reading materials. AIedu serves over 4,000 nurseries and kindergartens with 40,000 educators, providing an innovative approach to early childhood education through its use of AI technology. Its flagship product, Little Egg, has received positive feedback from parents and educators alike for its ability to provide personalized learning experience for each student.

POWERBRIDGE TECHNOLOGIES UNVEILS PLANS TO LEVERAGE CHATGPT TECHNOLOGY FOR EARLY CHILDHOOD EDUCATION

Robot hand touching fingertips with human hand through a screen. represents ai and machine learning stocks

ZHUHAI, China, Feb. 13, 2023 /PRNewswire/ — Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a leading provider of multi-industry technology solutions, is pleased to announce its plan to integrate ChatGPT technology into the AI-powered online educational services provided by its subsidiary, Ascendent Insights Education Co., Ltd. (“AIedu”).

AIedu is a provider of AI-powered apps and online educational services focusing on guided-reading solutions, with over 20,000 reading materials and a user base of more than 400,000 young children. It serves over 4,000 nurseries and kindergartens with 40,000 educators supported by 10 operational centers and 150 city partners across China.

The integration of ChatGPT technology will enhance our services and provide a more interactive and engaging learning experience for young children. Additionally, the utilization of ChatGPT technology in our early childhood educational apps has the potential to be a game-changer by enabling engaging audio interactions, innovative online creation, and immersive virtual study tours. Our interactive and effective educational apps are expected to be popular among children.

Stewart Lor, CEO of Powerbridge Technologies, commented: “We believe that ChatGPT has the potential to bring significant transformation in the education industry. We are excited to provide a whole new education experience for young children through the use ChatGPT technology. We expect to continue driving growth for the Company and provide attractive returns for our investors.

POWERBRIDGE TECHNOLOGIES ANNOUNCES STRATEGIC JOINT VENTURE TO DRIVE DIGITAL FINANCIAL INNOVATION FOR AGRICULTURE AND LIVESTOCK INDUSTRIES

ZHUHAI, China, July 6, 2023 /PRNewswire/ — Powerbridge Technologies, a provider of multi-industry technology solutions (Nasdaq: PBTS), has announced a strategic joint venture to establish Agro Digital Fintech Co., Ltd. (“Agro Digital or the Company”), a fintech and asset digitization company focused on the agriculture and livestock farming industries. The Company aims to create a robust digital financial ecosystem that drives value creation and leverages China’s Rural Revitalization Initiative (“the Initiative”).

The Initiative is a long-term development plan aimed at promoting economic growth, improving living standards, and addressing the challenges faced by rural areas in the country, including poverty alleviation, infrastructure development, agricultural modernization, rural entrepreneurship, and improvement of social services. The Initiative is focused on bridging the economic and social gap between rural and urban areas, promoting sustainable agriculture, and enhancing the overall well-being of rural communities. The market size brought by the Initiative is expected to reach approximately 4.5 Trillion U.S. Dollars by 2025.

Agro Digital utilizes advanced technologies such as IoT, blockchain, AI, and big data to build an innovative fintech platform helps drive the digital transformation of the agriculture and livestock industries, enabling the digital encapsulation of production and transaction processes. By leveraging digital data, the Company assists customers enhancing their financial profiles and improving their access to credit and financial services. The platform also allows financial institutions and funders to gain a comprehensive understanding of customers’ businesses, leading to more accurate risk assessments and tailored financial services solutions.

Stewart Lor, CEO of Powerbridge Technologies commented: “We are delighted to launch Agro Digital to leverage on the huge market opportunities by the Initiative in the next few years. By utilizing cutting-edge technologies and fostering financial inclusion, the Company can help empower rural communities and promote sustainable agricultural practices. We believe Agro Digital will contribute to our overall growth and bring values to our partners and investors.”]

POWERBRIDGE TECHNOLOGIES ANNOUNCES MEASURES TO MAINTAIN NASDAQ LISTING STATUS, DRIVE GROWTH POTENTIAL, AND ENHANCE FUTURE ACQUISITION OPPORTUNITIES

ZHUHAI, China, May 10, 2023 /PRNewswire/ — Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (the “Company”, “Powerbridge”, or “PBTS”), a provider of multi-industry technology solutions, is pleased to announce upcoming measures to maintain continued listing status on the Nasdaq exchange, supporting the Company’s long-term growth strategy and bolstering its access to favorable positioning in current and upcoming acquisition negotiations.

“We continue to prioritize the financial interests of our entire shareholder base above all other concerns,” commented Powerbridge CEO, Mr. Stewart Lor. “We are confident that maintaining our uninterrupted status as a Nasdaq-listed stock is our most effective path to achieving both our near-term growth objectives and our long-term vision as an emerging global leader with diversified exposure to next generation technology verticals.”

Powerbridge has made significant investments in SaaS, ePlatforms, and Smart Devices for global trade, travel and leisure, education, and digital assets, with a base that now spans a broad range of clients from global trade and cross-border participants to retail customers and educators.

The Company’s recent moves include its announced plan to further enhance ChatGPT as an educational technology services asset, its acquisition of a majority stake in several high growth technology companies, its strategic engagement in AI and Blockchain technology companies, and its development of metaverse and NFT solutions targeting multiple industries.

Lor added, “Since establishing our Nasdaq listed status, we have been able to massively expand our strategic footprint, gaining traction in a wide range of emerging growth technology markets, including metaverse development, AI-driven ed-tech, and cryptocurrency. We believe these investments have already laid a powerful foundation with tremendous long-term upside potential targeting the core industries best positioned to define the growth economy of the 21st century.”

As commented in the Company’s release dated April 28, 2023, Powerbridge management believes it can regain full Nasdaq listing compliance upon the completion of a 1-for-30 reverse stock split of the Company’s securities.

“We have planted the seeds of a robust value proposition,” concluded Lor. “The steps we take now to support the full actualization of that vision are an expression of the faith we have in our long-term strategic roadmap as well as our commitment to delivering on the faith our shareholders have placed in Powerbridge as demonstrated through their loyalty and support over many years—something we see as our most valuable asset. We look forward to cementing our compliance status and aggressively pursuing fresh opportunities aligned with our long-term vision.”

POWERBRIDGE TECHNOLOGIES LAUNCHES WEB 3.0 CRYPTOCURRENCY ETF PLATFORM

ETF and graph is written by hand on blackboard

ZHUHAI, China, Feb. 21, 2023 /PRNewswire/ — Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a provider of multi-industry technology solutions, is pleased to announce the launch of its decentralized cryptocurrency ETF platform (“Powerbridge ETF Platform” or the “Platform”) based on the cutting-edge Web 3.0 technology.

Powerbridge ETF Platform provides a decentralized and transparent network based on  Web 3.0 technology. The Platform utilizes big data analysis to select cryptocurrency index funds, reducing human bias and empowering users to manage their own assets and data without the need for third-party intermediaries. The Platform generates index fund products based on trading strategies and preferences of majority traders across a variety of cryptocurrencies. This allows users to take advantage of market trends and opportunities with a secure and convenient way to trade and manage cryptoassets.

Stewart Lor, CEO of Powerbridge Technologies commented: “We are excited with the launch of Powerbridge ETF Platform for cryptocurrencies. I believe our platform offers users a better way to trade and manage their crypto assets. We are continuing working with a network of partners to bring our Platform to market. I expect our Platform will contribute to our overall growth.”

POWERBRIDGE TECHNOLOGIES ANNOUNCES THE STRATEGIC ACQUISITION OF DTI GROUP TO EXPAND ITS OPERATIONS IN TRADE DIGITALIZATION

ZHUHAI, China, Nov 14, 2022 /PRNewswire/ — Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a provider of multi-industry technology solutions, announces that the Company has acquired 19% stake of DTI Group Limited (“DTI”), a technology company specializing in international trade digitalization and platforms.

The acquisition is consistent with the Company’s development plan and contributes to the expansion of its operations by building a trade digitalization ecosystem. DTI is one of the leading platform developers and service providers for Digital Trading Infrastructure & Online Dispute Resolution, a global project initiated by the United Nations Conference on Trade and Development. With the strategic acquisition, Powerbridge and DTI will be working closely together to implement the United Nation’s project (the “Project”).

The objective of the Project is to enhance digital trade connectivity and operations among online cross-border trade platforms and offline trade hubs in order to empower both the established and new global trade players. The Project will also be equipped with various digital trade systems that encourage cooperation and communications among local and global players, which is designed to increase the overall efficiency of cross-border trade and e-commerce.

Stewart Lor, CEO of Powerbridge commented: “We see that the market demand for international trade digitalization is growing rapidly. We look forward to working with DTI to integrate our technology and market resources in developing and implementing the United Nation’s Project. We believe this acquisition is critical to our growth and will enhance investor value.”

NEWS

  • PR Newswire•2 days agoPowerbridge Technologies, a provider of multi-industry technology solutions (Nasdaq: PBTS), has announced a strategic joint venture to establish Agro Digital Fintech Co., Ltd. (“Agro Digital or the Company”), a fintech and asset digitization company focused on the agriculture and livestock farming industries. The Company aims to create a robust digital financial ecosystem that drives value creation and leverages China’s Rural Revitalization Initiative (“the Initiative”).
  • PR Newswire•25 days agoPowerbridge Technologies (Nasdaq: PBTS), a leading provider of multi-industry technology solutions, has announced it has secured a second contract with OPPO, a globally recognized smart device manufacturer to implement Powerbridge Customs Clearance System (G-CIS) for OPPO’s export operations in Southeast Asia.
  • PR Newswire•last monthPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (the “Company” or “Powerbridge”), a provider of multi-industry technology solutions, today announced the closing of its 1-for-30 share consolidation of its ordinary shares (the “Share Consolidation”) effective immediately after the close of trading on Nasdaq Capital Market on June 8, 2023, and the Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of trading on June 9, 2023. At market open on June 9,
  • PR Newswire•2 months agoPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (the “Company”, “Powerbridge”, or “PBTS”), a provider of multi-industry technology solutions, is pleased to announce upcoming measures to maintain continued listing status on the Nasdaq exchange, supporting the Company’s long-term growth strategy and bolstering its access to favorable positioning in current and upcoming acquisition negotiations.
  • PR Newswire•2 months agoPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (the “Company” or “PBTS”), a provider of multi-industry technology solutions, today announced that it has requested a hearing before the Nasdaq Hearings Panel as the next step in the process in seeking an extension to satisfy the minimum bid price requirement set forth in Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market (“Nasdaq”
  • PR Newswire•3 months agoPOWERBRIDGE TECHNOLOGIES INVESTS IN HIGH-PERFORMANCE CRYPTO MINING EQUIPMENTPowerbridge Technologies, a provider of multi-industry technology solutions (Nasdaq: PBTS), has announced its recent acquisition of 1,200 units of A1346 Avalon Bitcoin Miners. The investment aligns with the Company’s long-term strategy in the crypto market.
  • PR Newswire•3 months agoPOWERBRIDGE TECHNOLOGIES ACQUIRES AIEDU, UNLOCKING NEW AVENUES FOR CHATGPT APPLICATIONSPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a leading provider of multi-industry technology solutions, today announced it has acquired 90% stake of Ascendent Insights Education Co., Ltd. (“AIedu”), an AI education service company. This move is part of Powerbridge’s strategy to expand its presence in the education industry and leverage AIedu’s expertise to further improve its offerings.
  • PR Newswire•3 months agoPOWERBRIDGE TECHNOLOGIES ACQUIRES MAJORITY STAKE IN DTI GROUP TO BUILD TRADE DIGITALIZATION ECOSYSTEMPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a provider of multi-industry technology solutions, has announced today that it has successfully acquired a majority stake of 51% in DTI Group, a leading platform developer and service provider for digital trade infrastructure in China.
  • PR Newswire•3 months agoCORPORATE OVERVIEW AND SHAREHOLDER UPDATE FOR POWERBRIDGE TECHNOLOGIESWith 25 years of experience, Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), is an established provider of a broad spectrum of digital solutions and technology services. The Company’s offerings range from SaaS to ePlatforms and to Smart Devices for global trade, education, travel and leisure, and digital assets. Powerbridge’s clients span a diverse range of global trade and cross-border participants to retail customers and educators. Since listed on Nasdaq, Po
  • PR Newswire•4 months ago POWERBRIDGE TECHNOLOGIES UNVEILS HNT ROUTER MINER FOR DECENTRALIZED WIRELESS NETWORK CONNECTIVITYPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a provider of multi-industry technology solutions, has announced that Powerbridge has successfully developed the prototype of HNT Router Miner and software system based on the Helium network. The Helium Network is a decentralized wireless network designed to provide efficient connectivity for IoT devices.
  • PR Newswire•5 months ago POWERBRIDGE TECHNOLOGIES LAUNCHES WEB 3.0 CRYPTOCURRENCY ETF PLATFORMPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a provider of multi-industry technology solutions, is pleased to announce the launch of its decentralized cryptocurrency ETF platform (“Powerbridge ETF Platform” or the “Platform”) based on the cutting-edge Web 3.0 technology.
  • PR Newswire•5 months ago POWERBRIDGE TECHNOLOGIES UNVEILS PLANS TO LEVERAGE CHATGPT TECHNOLOGY FOR EARLY CHILDHOOD EDUCATIONPowerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a leading provider of multi-industry technology solutions, is pleased to announce its plan to integrate ChatGPT technology into the AI-powered online educational services provided by its subsidiary, Ascendent Insights Education Co., Ltd. (“AIedu”).
  • PR Newswire•8 months ago Powerbridge Technologies Co., Ltd. (Nasdaq: PBTS) (“Powerbridge” or the “Company”), a provider of multi-industry technology solutions, announces that the Company has acquired 19% stake of DTI Group Limited (“DTI”), a technology company specializing in international trade digitalization and platforms.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, EDM MEDIA LLC FOR A ONE DAY PBTS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.